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A new protocol for functionalization of zirconocyclopentenes formed by Negishi 
bicyclization of 1,7- and 1,6-enynes is described. Regioselective transfer of the alkyl 
ligand to select boron electrophiles followed by oxidation provides 1-alkylidene-2-
hydroxymethylcycloalkanes in yields comparable to protonation of the zirconocycles. 
The scope and limitations of Mukaiyama’s cobalt-mediated oxidative cyclization 
of 4-alkene-1-ols are detailed with a focus on the effects of substitution patterns on 
efficiency and stereochemistry. Additionally, improvements in the ligand and cobalt 
complex syntheses are discussed.  
Additionally, modular syntheses of two Annonaceous acetogenin analogs are 
described. The flexible approach allows for rapid synthesis of analogs through late stage 
diversification, allowing the elucidation of structure activity relationships (SARs). 
 vii
Table of Contents 
List of Tables ...........................................................................................................x 
List of Figures ........................................................................................................ xi 
List of Schemes..................................................................................................... xii 
List of Abbreviations .............................................................................................xv 
Chapter 1: Selective Oxidation of Zirconocyclopentenes Via Organoboranes .......1 
1.1 Introduction............................................................................................1 
1.1.1 Reactivity of hydrozirconation products.......................................1 
1.1.2 Transmetallation of hydrozirconation products ............................4 
1.2  Zirconocycles...........................................................................................7 
1.2.1 Methods of Formation...................................................................7 
1.2.2 Reactions of zirconocycles .........................................................10 
1.2.2.1 Zirconocyclopentenes .....................................................11 
1.2.2.2 Transmetallation of zirconocyclopentenes......................13 
1.3 Objective of the current study.................................................................14 
1.4 Results and discussion ............................................................................15 
1.4.1 Substrate preparation ..................................................................15 
1.4.2 Control experiments....................................................................17 
1.4.3 Scope and limitations..................................................................20 
1.5 Conclusion ..............................................................................................27 
Chapter 2: Cobalt-Mediated Oxidation of 4-Alkenols...........................................28 
2.1  Introduction............................................................................................28 
2.2  Previous approaches to the monoprotected bis-THF.............................29 
2.3  Origin of the cobalt oxidation of bis-homoallylic alcohols ...................31 
2.4  Objectives of the current research..........................................................33 
2.5 Results and discussion .........................................................................34 
2.5.1 Ligand and catalyst preparation ..................................................34 
2.5.2 Substrate preparation ..................................................................35 
 viii
2.5.3 Evaluation of oxidation conditions .............................................39 
2.5.4 Scope and limitations..................................................................41 
2.6 Conclusion ...........................................................................................45 
Chapter 3: Annonaceous Acetogenins ...................................................................47 
3.1 Introduction..........................................................................................47 
3.2 Proposed modes of action ....................................................................48 
3.2.1 Mitochondrial complex I inhibition ............................................48 
3.2.2 Inhibition of ubiquinone-linked NADH oxidase ........................49 
3.3 Structure activity relationships ............................................................49 
3.3.1 Inhibition studies.........................................................................49 
3.3.2 Cytotoxicity Studies....................................................................52 
3.4 Objective of the current work ..............................................................53 
3.5 Previously reported syntheses of bullatacin.........................................54 
3.5.1 Sasaki’s synthesis of bullatacin ..................................................54 
3.5.2 Keinan’s synthesis of bullatacin and squamotacin .....................56 
3.5.3 Hoye’s synthesis of bullatacin ....................................................57 
3.5.4 Roush’s synthesis of bullatacin...................................................59 
Chapter 4: Synthesis of Acetogenin Analogs ........................................................61 
4.1 Retrosynthetic analysis ........................................................................61 
4.2 Synthesis of the bis-THF core..............................................................62 
4.3 Introduction of the alkyl chain.............................................................63 
4.4 The tether .............................................................................................64 
4.4.1 Synthesis of the tether.................................................................64 
4.4.2 Incorporation of the tether ..........................................................65 
4.5 Synthesis of the epoxy butenolide .......................................................66 
4.6 Final assembly of the tether-elongated bullatacin analog....................67 
4.7 22-Deoxy analog of squamotacin ........................................................68 
4.7.1 Introduction of the terminal alkyl chain......................................68 
4.7.2 Synthesis of the tether precursor.................................................69 
4.7.3 Completion of 22-deoxysquamotacin .........................................70 
 ix
4.8 Conclusion ...........................................................................................72 
CHAPTER 5: EXPERIMENTAL PROCEDURES...........................................................73 
5.1 General procedures ..............................................................................73 
5.2 Enyne substrate preparation.................................................................74 
5.3 Zirconocylopentene protonation control experiments .........................80 
5.4 Boron-mediated oxidation of zirconocyclopentenes ...........................86 
5.5 Modp Ligand and cobalt catalyst synthesis .........................................97 
5.6 Synthesis and cobalt-mediated oxidation of 4-alkenols.......................99 
5.7 Synthesis of the tether-elongated analog of bullatacin ......................118 
5.8 Synthesis of 22-deoxy-squamotacin ..................................................129 
References............................................................................................................141 
 x
List of Tables 
Table 1.1 Control oxidations of the zirconocycle from enyne 1.1a..................18 
Table 1.2 Screening of boron electrophiles for transmetallation ......................19 
Table 1.3 Transmetallation/oxidation of enyne substrates using 
(cHex)2BCl ........................................................................................21 
Table 1.4 Transmetallation/oxidation of enyne substrates using 
(cHex)2BCl (cont’d) ..........................................................................22 
Table 2.1 Cytotoxicity profiles of acetogenins 2.16 and 2.17 for lung, 
colon and renal cancer cell lines51 ....................................................29 
Table 2.2 Mukaiyama’s aerobic peroxidation of alkenes .................................32 
Table 2.3 Cobalt-catalyzed hydration of alkenes and cyclization of bis-
homoallylic alcohols .........................................................................33 
Table 2.4 Evaluation of reaction conditions .....................................................41 
Table 2.5 Summary of oxidation results ...........................................................43 
Table 2.6 Summary of oxidation results (cont’d) .............................................44 
Table 3.1 Acetogenin SAR study of NADH oxidase inhibition .......................50 
Table 3.2 Acetogenin SAR study of NADH oxidase inhibition (cont’d) .........51 




List of Figures 
Figure 1.1 ORTEP representation of diol 1.8g...................................................24 
Figure 1.2 Isomerization vs. TBS-deprotection of the zirconocycle from 
enyne 1.8a .........................................................................................25 
Figure 2.1 Annonaceous acetogenins bullatacin and squamotacin ....................28 
Figure 3.1 Representative structure of selected Annonaceous acetogenins.......47 
Figure 3.2 McLaughlin’s model for acetogenin inhibition of mitochondrial 
complex I ..........................................................................................48 
Figure 3.3 Tether length-dependent membrane conformations of acetogenins .52 
 
 xii
List of Schemes 
Scheme 1.1 Hydrozirconation of alkenes and alkynes .....................................1 
Scheme 1.2 General reactions of hydrozirconation products ...........................2 
Scheme 1.3 Insertion reactions of alkyl and alkenylzirconocoenes .................3 
Scheme 1.4 Reactions of cationic zirconocene complexes with aldehydes 
and epoxides..................................................................................4 
Scheme 1.5 Applications of transmetallation from Zr to Cu............................5 
Scheme 1.6 Examples of transmetallation from Zr to Ni and Pd .....................6 
Scheme 1.7 Transmetallations from Zr to Zn...................................................6 
Scheme 1.8 Rausch’s synthesis of a zirconocylopentadiene............................7 
Scheme 1.9 Erker’s approach to benzyne adducts of zirconocene...................8 
Scheme 1.10 Buchwald’s modification of Erker’s method................................9 
Scheme 1.11 Negishi’s zirconocyclopropane.....................................................9 
Scheme 1.12 Formation of bicyclozirconocyclopentenes by Negishi’s 
method.........................................................................................10 
Scheme 1.13 Carbon monoxide insertion into zirconocylopentenes and 
zirconocyclopentanes..................................................................11 
Scheme 1.14 Fagan and Nugent’s synthesis of main group heterocycles ........11 
Scheme 1.15 Regioselective migratory insertion reactions of 
zirconocyclopentenes..................................................................12 
Scheme 1.16 Takahashi’s regioselective halogenations of 
zirconocyclopentenes..................................................................13 
Scheme 1.17 Regioselective transmetallations of zirconocyclopentenes to 
Cu................................................................................................14 
 xiii
Scheme 1.18 Potential applications of zirconocyclopentene transfer to 
boron ...........................................................................................15 
Scheme 1.19 Preparation of enynes 1.1a , 1.2a, 1.4a.......................................16 
Scheme 1.20 Synthesis of enynes 1.5a and 1.13a ............................................17 
Scheme 1.21 Synthesis of enyne substrates 1.8a, 1.9a, 1.10a and 1.15a.........17 
Scheme 1.22 Cis-selective cyclization reported by RajanBabu .......................22 
Scheme 1.23 Proposed rationale for selective deprotection of the E-isomer ...25 
Scheme 1.24 Acid-catalyzed isomerization of allylic silyl alkene 1.8g to 
ketone 1.8h..................................................................................26 
Scheme 2.1 Monoprotected bis-THF diol 2.18 as a precursor to 
Annonaceous acetogenin analogs ...............................................29 
Scheme 2.2   Koert’s approach to the bis-THF core of acetogenins ................30 
Scheme 2.3 Wang and Shi’s approach to the bis-THF core...........................31 
Scheme 2.4 Synthesis of the modp ligand and its cobalt complex.................35 
Scheme 2.5 Synthesis of substrates 2.27a-2.31a from 
hydrocinnamaldehyde .................................................................36 
Scheme 2.6 Synthesis of 2-substituted alkenol 2.33a ....................................37 
Scheme 2.7 Synthesis of γ-substituted subtrate 2.37a....................................37 
Scheme 2.8 Synthesis of diene diols 2.23a and 2.41a, a fused-THF 
precursor .....................................................................................38 
Scheme 2.9 Synthesis of 2.43a, 2.18a and 2.45a ...........................................39 
Scheme 2.10 Synthesis of diol 2.46a................................................................39 
Scheme 2.11  Cis/trans isomerization control experiment................................42 
Scheme 3.1 Sasaki’s approach to bullatacin...................................................55 
Scheme 3.2 Sasaki’s approach to bullatacin (cont’d).....................................56 
 xiv
Scheme 3.3 Keinan’s synthesis of bullatacin .................................................57 
Scheme 3.4 Hoye’s synthesis of bullatacin ....................................................58 
Scheme 3.5 Hoye’s synthesis of bullatacin (cont’d) ......................................59 
Scheme 3.6 Roush’s synthesis of bullatacin (cont’d).....................................60 
Scheme 4.1 Retrosynthetic analysis ...............................................................61 
Scheme 4.2 Retrosynthetic analysis (cont’d) .................................................62 
Scheme 4.3 Synthesis of the bis-THF core.....................................................63 
Scheme 4.4 Stereoselective, direct formation of the erythro isomer..............64 
Scheme 4.5 Synthesis of tether precursor 4.82...............................................65 
Scheme 4.6 Incorporation of the tether ..........................................................66 
Scheme 4.7 Synthesis of epoxy butenolide 4.75 ............................................67 
Scheme 4.8 Completion of acetogenin analog 4.89 .......................................68 
Scheme 4.9 Formation of the deoxy analog precursor by Wittig 
olefination ...................................................................................69 
Scheme 4.10 Synthesis of tether precursor 4.92...............................................69 
Scheme 4.11 Incorporation of the tether ..........................................................70 
Scheme 4.12 Addition of alkyne 4.97 to the epoxy butenolide........................71 
Scheme 4.13  Solution to the low yield of DDQ debenzylation of 4.98 ...........71 
 xv
 List of Abbreviations 
Ac Acetate 
9-BBN 9-Borabicyclo[3,3,1]nonane 





CAM Ceric ammonium molybdate 






ED50 Effective dosage 
Et Ethyl 
FID Flame ionization detector 
FT-IR Fourier transform-infrared 
GC Gas Chromatography 
GOESY Gradient Overhauser effect spectroscopy 








NMO N-methylmorpholine N-oxide 
NMR Nuclear Magnetic Resonance 
NOE Nuclear Overhauser Effect 
ORTEP Oak Ridge Thermal-Ellipsoid Plot 
[O] Oxidation 




Rf Retention time 
TBS tert-Buyldimethylsilyl 
TEMPO 2,2,6,6-Tetramethyl piperidine N-oxide 
Tf Triflate or Trifluoromethylsulfonyl 
THF Tetrahydofuran 
TLC Thin Layer Chromatography 
TMS Trimethylsilyl 








While Wilkinson’s 1953 report of zirconocene dibromide was among the earliest 
examples of metallocene complexes,1 application of zirconocene complexes to organic 
chemistry matured slowly until the 1970s.2 Preferential disubstitution and facile β-
hydride elimination greatly limited metathesis approaches employing organolithiums and 
Grignard reagents.2 A breakthrough in this research area was Wailes’ discovery of 
chlorozirconocene hydride (HZrClCp2) and its hydrozirconation reactions with alkenes 
and alkynes.3 Schwartz later studied these reactions more extensively, determining the 
scope and limitations and examining applications to organic synthesis.4 This first, general 
route to organozirconocene compounds has provided valuable information regarding their 
reactivity. 











1.1.1 Reactivity of hydrozirconation products 
 
Having examined the scope of the hydrozirconation reaction, Schwartz’s group 
began to explore reactions of the resulting alkyl and alkenylzirconocenes. They found 
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that these monoorganylzirconocenes react readily with electrophilic halogenating agents 
such as Br2, I2, NBS and NCS to provide alkyl halides and haloalkenes (Scheme 1.2).4 
Similarly, oxidation of alkylzirconocenes with O2 or electrophilic oxidizing reagents such 
as t-BuOOH, m-CPBA or H2O2 provides the corresponding alcohols.4,5 However, similar 
attempts to oxidize alkenylzirconocenes to aldehydes or ketones have proven less 
successful.2 




















Another significant contribution to organozirconium chemistry was the discovery 
that carbon monoxide inserts into the C-Zr bond of most alkyl and alkenylzirconocenes to 
provide acylzirconium compounds (Scheme 1.3).6 Subsequent treatment of these 
intermediates with protic acid provides the corresponding aldehydes or with electrophilic 
halogenating reagents provides acid halides, carboxylic acids or esters depending on 
workup conditions. Similar insertion reactions have been reported with isonitriles to 
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provide iminoacylzirconium intermediates,7 which can either be treated with 
halogenating reagents to provide nitriles8 or hydrolyzed to give aldehydes.9 
























Despite these advances, the organozirconocenes formed by hydrozirconation are 
relatively unreactive toward many common organic electrophiles, likely due to the 
crowded Zr coordination sphere.2 Specifically, many of the C-C bond forming reactions 
integral to organic synthesis such as aldehyde additions, additions to α,β-unsaturated 
ketones,10 epoxide opening and SN2 reactions with alkyl halides are largely unavailable 
with hydrozirconation products.2 One solution to this problem has been the use of Ag(I) 
salts such as AgAsF6 to increase the Lewis acidity and reduce the steric environment of 
the metal by halogen abstraction.11 This has allowed for successful addition to aldehydes 
and an interesting isomerization/addition reaction with epoxides (Scheme 1.4). A second, 
more general approach to the problem of low reactivity is transmetallation. By transfer of 
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the alkyl or alkenyl group to another metal, the utility of organozirconocenes has been 
expanded immensely.  














1.1.2 Transmetallation of hydrozirconation products 
 
For transmetallation to be favorable, a difference in electronegativity between the 
two metals is necessary, which is strongly influenced by the electron donating or electron 
withdrawing nature of each. Examples of transmetallations of organozirconocenes to 
various transition and main group metals have been reported including Cu, Pd, Ni, Sn, 
Hg, B, Al and Si.2,12a By using this strategy, the chemistry of relatively unreactive 
organozirconocenes has been joined with the wealth of reactions available to other 
metals.  
Examples of this approach include the transfer of organic ligands from Zr to Cu, 
accessing additions to α,β-unsaturated ketones12  and epoxides13 as well as substitution 
reactions with alkyl triflates,13 allylic and benzylic halides and phosphates,14 and vinyl 
halides and sulfonates (Scheme 1.5).13 Transmetallation of alkenylzirconocenes to Ni and 
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Pd has also been applied to allylic substitution reactions and cross-couplings with vinyl 
halide (Scheme 1.6)12d,15 Transmetallation of hydrozirconation products to Zn has 
provided organozinc intermediates useful in additions to aldehydes16 and as secondary 
transfer agents to other metals (Scheme 1.7).17 Additionally, transfer of hydrozirconation 
products to B has provided a solution to the problematic oxidation of 
alkenylzirconocenes.18  









































































1.2  ZIRCONOCYCLES 
1.2.1 Methods of Formation 
 
 Rausch reported an early example of zirconocyle formation that provided insight 
into this chemistry by photolysis of dimethylzirconocene in the presence of 
diphenylacetylene (Scheme 1.8).19 Homolytic cleavage of the methyl groups provided a 
transient Zr(II) complex, which formed a π-complex with the alkyne. Since Zr(II) has a 
lone pair of electrons available for back bonding, this π-complex could also be viewed as 
a Zr(IV) zirconocyclopropene. This intermediate underwent further ring expansion with 
an additional equivalent of the alkyne to produce a zirconocyclopentadiene. Related 
approaches to zirconocycles involving reduction of zirconocene(IV) dichloride to 
zirconocene(II) with Na/Hg or Mg/HgCl2 in the presence of π-systems have also been 
reported.20 However, more recent methods based on thermal decomposition of 
diorganozirconocenes currently offer the most general and reliable route to zirconocycles. 





















Erker observed that when diphenylzirconocene was thermolyzed in hydrocarbon 
solvents, benzene and a benzyne π-complex of zirconocene (or zirconocyclopropene) 
were formed (Scheme 1.9).21 He studied the mechanism of this reaction and found that a 
β-H of one phenyl was abstracted by the Zr-C bond of the second phenyl group.22 The 
resulting, highly strained complexes reacted readily with other π-systems including 
alkenes, alkynes, aldehydes and imines to give 5-membered zirconocycles. An elegant 
and practical modification to Erker’s method, which effectively wasted one of the organic 
groups, was introduced by Buchwald.23 Formation of mixed diorganozirconocenes by 
reactions of alkyl, alkenyl and aryllithiums with methylzirconocene chloride allowed the 
methyl group to serve as the sacrificial ligand (Scheme 1.10). These approaches to π-
complexes of zirconocene have proven very useful when the “free” π-system is unstable 
(benzynes) or incompatible with other methods (terminal alkynes). 

























 A complementary method for the preparation of zirconocycles from stable π-
systems was described in the 1980’s by Negishi and coworkers.24  They found that 
dibutylzirconocene, produced from the metathesis reaction between n-BuLi and 
zirconocene dichloride, decomposes cleanly at relatively low temperatures (0 °C to rt) to 
provide a zirconocyclopropane (Scheme 1.11). This reagent may be used as a precursor 
to other zirconocycles including zirconocyclopentanes, zirconocyclopentenes, 
zirconocyclopentadienes by ring-expansion and ring-contraction in the presence of 
alkenes, alkynes, aldehydes or nitriles. 











 Negishi also reported a useful application of this method in the bicyclization of 
1,6- and 1,7-dienes, diynes and enynes.25 In the case of enyne bicyclization, the initial 
zirconocyclopropane reacts with the alkyne to form a zirconocyclopentene (Scheme 
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1.12). This intermediate undergoes ring-contraction, producing a zirconocyclopropene 
that can react intramolecularly with the pendant alkene to form a 
bicyclozirconocyclopentene. Similarly, treatment of with dienes and diynes has been used 
in the formation of bicyclic zirconocyclopentanes and zirconocyclopentadienes, 
respectively. 














1.2.2 Reactions of zirconocycles 
 
 The reactivity of zirconocycles largely follows that of hydrozirconation products, 
but notable distinctions exist mainly due to the presence of the second C-Zr bond. For 
example, reaction of zirconocyclopentanes26 and zirconocylopentenes25 with carbon 
monoxide initially gives the expected acylzirconium intermediates. However, the 
additional C-Zr undergoes facile insertion as well, providing cyclopentanones or 
cyclopentenones, respectively (Scheme 1.13). Similarly, Fagan and Nugent showed that 
both C-Zr bonds of zirconocylopentadienes transfer to main group electrophiles to form 
the corresponding heterocycles (Scheme 1.14).27 
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E = PhP, PhAs, PhSb, PhBi
PhB, SiBr4, GeCl2  
1.2.2.1 Zirconocyclopentenes 
 
 Containing both a Csp3-Zr and a Csp2-Zr bond, zirconocyclopentenes elicit a 
question of regioselectivity. One of the earliest examples of a regioselective reaction of 
these complexes was reported by Negishi in the migratory insertion of isonitriles, which 
occurs regioselectively at the Csp3-Zr bond.9 In contrast to reactions with carbon dioxide, 
a second migratory insertion occurs less readily for isonitriles, making the acyliminium 
species a viable synthetic intermediate (Scheme 1.15). Similar regioselectivity has been 
observed for migratory insertion of acetylides28 and allenyl carbenoids.29  
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Negishi also found that the reactivity of zirconocyclopentenes is somewhat 
enhanced relative to hydrozirconation products as reactions with aldehydes proceed 
efficiently and regioselectively at the alkyl zirconium bond.30 Monoprotonation of 
zirconocylcopentenes is also selective for the Csp3-Zr bond, producing an 
alkenylzirconium species available for further transformation.31 Additionally, Takahashi 
and coworkers investigated the regioselective halogenation of zirconocyclopentenes, 
providing convenient reagent-controlled methods for formation of either the vinyl halide 
or the homoallylic halide (Scheme 1.16).31,32 Notably, the regioselectivity of iodination 
using I2 was highly dependent on the substitution of the alkyne used for zirconocycle 
formation as aryl alkynes provided the vinyl iodide while alkyl-substituted gave the 
homoallylic iodide.  
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1.2.2.2 Transmetallation of zirconocyclopentenes 
 
 As with hydrozirconation products, transmetallation has expanded the reactions 
available to zirconocyclopentenes, but with much fewer examples reported in the 
literature. Lipshutz observed that zirconocyclopentenes react selectively with copper 
halides at the Csp2-Zr bond to produce alkenylcopper species (Scheme 1.17). The 
resulting mixed-dimetallated species have been used successfully in conjugate additions 
to α,β-unsaturated ketones and substitutions of allylic halides.33 Takahashi later 
developed a complementary modification, using selective protonation of the C-Cu bond 
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followed by transmetallation of the remaining Csp3-Zr bond to Cu and reaction with allyl 
chloride, effecting substitution at the Csp3 site.34 























1.3 OBJECTIVE OF THE CURRENT STUDY 
 
 Our interest in this arena has focused on further increasing the synthetic utility of 
zirconocyclopentenes through transmetallation to boron. Inspired by Cole’s and Nugent’s 
transmetallation of other zirconocycles to boron and the regioselective reactions of 
zirconocylopentenes, we hoped to bridge the chemistry of bicyclization reactions of 1,6 
and 1,7-enynes with the rich chemistry of organoboranes. It was envisioned that transfer 
of one or both C-Zr bonds to boron followed by oxidation, homologation,35 
carbonylation36 or Suzuki coupling37 would enhance the usefulness of these zirconocycles 
(Scheme 1.18). In the current study the regioselectivity and efficiency of transmetallation 
to boron electrophiles followed by oxidation of the C-B bond was investigated as a proof 
of concept.   
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1.4 RESULTS AND DISCUSSION 
1.4.1 Substrate preparation 
 
A representative set of enynes was prepared to examine the scope and limitations 
of the boron-mediated oxidation of zirconocyclopentenes. Malonate-derived enynes 1.1a 
and 1.2a were prepared by deprotonation of terminal alkyne 1.338 with n-BuLi and 
treatment of the resulting acetylide with MeI and Me3SiCl, respectively (Scheme 1.19). 
Phenyl-substituted alkyne 1.4a was prepared from 1.3 and iodobenzene using standard 
Sonogashira conditions.39 Enyne 1.5a was prepared by addition of vinylmagnesium 
bromide to 4-pentynal followed by benzylation of the resulting alcohol and methylation 
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of the terminal alkyne with n-BuLi/MeI (Scheme 1.20). Enynes 1.8a, 1.9a and 1.10a 
were prepared by addition of the corresponding lithium acetylides to aldehyde 1.11 
followed by treatment of the resulting alkoxide with TBSCl (Scheme 1.21).40 A similar 
reaction using 5-hexenal provided 1,7-enyne 1.13a (Scheme 1.20). Treatment of TMS-
substituted alkyne 1.8a with catalytic NaOH in MeOH provided terminal alkyne 1.14, 
which was treated with n-BuLi followed by MeI to provide enyne 1.15a (Scheme 1.21).  











1.1a, X = I, R = Me, 89%








































1.8a, R = Me3Si (87%)
1.9a, R = Ph (90%)
1.10a, R = p-Cl(C6H4) (71%)
1.11
 
1.4.2 Control experiments 
 
The zirconocyclopentene derived from enyne 1.1a was chosen as a model for a 
series of control experiments examining the possibility of direct oxidation. All attempts 
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to oxidize this organozirconocene with reagents such as NMO, TEMPO, benzoyl 
peroxide were met with low yields and modest regioselectivities (Table 1.1).41 The major 
product in most cases was the cycloreduction product resulting from protonation either 
under reaction conditions or upon workup. While formation of this product with protic 
oxidants (entries 5-8) was unsurprising, aprotic oxidants offered little or no improvement 
(entries 1-4) and reaction of the zirconocyclopentene with O2 caused decomposition. 


















1.1b 1.1c 1.1d  
Entry Oxidant 1.1b 1.1c 1.1d
1 NMO 72 21 7 
2 TEMPO 95 5 0 
3 BzO2 87 3 10 
4 Me3NO 63 13 24 
5 H2O2, NaOH 96 4 0 
6 NaBO3 96 4 0 
7 t-BuOOH 81 19 0 
8 m-CPBA 80 20 0 
 
With only moderate yields and selectivity for these oxidations, transmetallation of 
the zirconocyclopentene formed from enyne 1.1a to boron was examined. The 
zirconocycle was treated with a variety of electrophilic boron reagents followed by a 
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standard oxidative workup with NaOH/H2O2 (Table 1.2).41 Transmetallation with BCl3 
produced a complex mixture of demethylation and oxidation products, indicating a need 
to modulate the Lewis acidity of the boron reagent.  Treatment of the zirconocycle with 
BBr3 produced cycloreduced product 1.1b, exclusively, while transmetallation with 
catechol-BBr, 9-BBN-Cl and (-)-Ipc2BCl provided minor amounts of oxidation product 
of alcohol 1.1c. These results suggest that the counter ion and steric requirements of the 
boron reagent have significant impact on transmetallation. Still, the high regioselectivity 
observed for the minor oxidation product (1.1c) was encouraging. The efficiency of the 
process was improved significantly without loss of regioselectivity by using Bu2BOTf. 
Further improvement was observed in the transmetallation with (cHex)2BCl, providing 
alcohol 1.1c in a useful yield of 75%. 

















Entry R2B-X 1.1b 1.1c 1.1d 
1 BCl3 11 5 0 







62 25 0 
4 9-BBN-Cl 79 11 0 
5 (-)-Ipc-BCl 59 24 0 
6 Bu2BOTf 8 57 0 
7 (cHex)2BCl 8 75 0 
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1.4.3 Scope and limitations 
 
The results of the boron-mediated regioselective oxidation of 
zirconocyclopentenes from the enynes synthesized above are summarized in Table 1.3. In 
particular, 1,6-enynes for zirconocycle formation due to favorable kinetics in the 
formation of a 5-membered rings and geminal substitution along the tether further 
enhances the rate and efficiency of cyclization due to the Thorpe-Ingold effect.42 While 
enynes without geminal substitution and 1,7-enynes still undergo the cyclization, a 
control experiment was deemed necessary to distinguish between the efficiency of 
zirconocycle formation versus the efficiency of the transmetallation/oxidation protocol. 
Accordingly, each zirconocycle intermediate was also protonated in a separate 
experiment to provide the corresponding cycloreduced product for comparison.  
Initially, yields for the transmetallation/oxidation reactions varied greatly which 
was attributed to decomposition of the (cHex)2BCl, likely through disproportionation, 
over time. As a remedy to this, the reagent was prepared fresh from dry box-stored 
(cHex)2BH  before each experiment. After instituting this practice, isolated yields for the 
transmetallation/oxidation protocol were generally close to yields for protonation. The 
reaction conditions were found compatible with various 1,6- and 1,7-enynes with alkyl- 
and aryl-substituted alkynes with no variation in regioselectivity. Significantly, the 
transmetallation/oxidation reaction conditions tolerated common alcohol protecting 
groups such as methyl, TBS and benzyl ethers.  
Enyne 1.5a gave a markedly lower yield of the oxidation product (38%) with a 
significant amount of cycloreduced product 1.5b (52%). The yield of the desired alcohol 
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was improved somewhat by extending the transmetallation reaction time from 3 h to 28 h 
(64%). The lower efficiency of transmetallation for this substrate is likely due to the 
electron-withdrawing nature and increased steric demand of the allylic benzyl ether, 
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Where applicable, relative stereochemistry was conserved between protonolysis 
and oxidation products, and followed previously observed trends43 for enynes 1.13a and 
1.5a. However, substrates 1.8a, 1.9a, 1.10a gave exclusively trans-isomers for both 
protonation and oxidation by GOESY NMR experiments, while enyne 1.15a gave a 
mixture of trans and cis (dr 1.6:1), contrary to RajanBabu’s report of cis-selectivity for a 
similar propargyl-substituted enyne (Scheme 1.22).44 





2.5 193%   
 
Substrates with silyl-substituted alkynes were of particular interest because of the 
synthetic utility of the vinyl silanes produced by the reaction.45 Indeed, the reactivity of 
the vinyl silanes produced made these enynes somewhat fickle substrates for both the 
























R = Me 
R = Ph 
R = p-Cl(C6H4) 













   
 23
oxidation and protonation experiments. Specifically, malonate-derived enyne 1.2a 
provided E/Z mixtures of products for both protonolysis (3 M HCl) and the 
transmetallation oxidation procedures. As the zirconocycle intermediate templates a 
specific olefin geometry, it was reasoned that isomerization was likely occurring after 
cleavage of the zirconocyle by acid or transmetallation. For protonation, it was found that 
simply substituting H2SO4 for HCl prevented isomerization and provided the 
cycloreduced product in excellent yield (95%). Since a major difference between these 
two acids is the lower basicity of the sulfate ion, the oxidative workup for the 
corresponding transmetallation was adjusted by using the less basic, preformed NaOOH 
rather than sequential addition of NaOH and H2O2.  Gratifyingly, this small modification 
provided the desired product 1.2ac as a single double bond isomer, albeit in a lower 64% 
yield.  
When this modified oxidative workup was extended to substrate 1.8a, the product 
was also obtained as the expected Z-isomer, but was apparently accompanied by the 
corresponding TBS-deprotected diol (31%). However, a single crystal of this diol suitable 
for X-ray crystallography was isolated, surprisingly revealing the E-olefin isomer 1.8g 
(Figure 1.1). Notably, attempts to desilylate the TBS-protected Z-isomer for comparison 
revealed that it was quite resistant to common methods including n-Bu4F, 1 M HCl and i-
Bu2AlH, requiring HF•pyridine, which provided Z-diol 1.8f along with protonolysis of 
the vinyl silane. 
Surprisingly, the formation of E-diol 1.8g was found to be dependent on the 
amount of (Chx)2BCl used during transmetallation (Figure 1.1). It was expected that an 
increase in the amount of the Lewis acidic chloroborane would cause more deprotection, 
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but the opposite was observed as a change from 1.5 to 2.3 eq of (Chx)2BCl shut down the 
deprotection entirely, providing an E/Z mixture of TBS ethers. The large steric demand of 
the Z-isomers formed during the reaction, with a TMS group adjacent to a TBS ether, and 
the ability of the silyl group to stabilize β-carbocations likely makes this substrate 
particularly susceptible to E/Z isomerization during the Lewis acidic conditions of 
transmetallation. A possible explanation for the selective deprotection of the E-isomer is 
that the intermediate chlorozirconocene participates in intramolecular cleavage of the 
silyl ether, which is unavailable for the Z-isomer (Scheme 1.23).  
Figure 1.1 ORTEP representation of diol 1.8g 
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Another interesting observation from the oxidization of the zirconocycle derived 
from enyne 1.8a was a further reaction of E-alkene diol 1.8f. Simply allowing an NMR 
sample in CDCl3 to stand, unprotected from light, caused isomerization to a single 
diastereomer of ketone 1.8h. It is well known that exposure of chloroform to light 
produces acid and that vinyl silanes react with acid to form β-carbocations. Diol 1.8g is 
particularly susceptible to protonation as the resultant carbocation is not only stabilized 
by silicon but is also tertiary. As such, the proposed mechanism for this reaction involves 
generation of the stabilized carbocation followed by a 1,2-Meerwein-Wagner hydride 
shift analogous to a pinacol rearrangement. Deprotonation of the resulting intermediate 
regenerated the acid catalyst and provided ketone 1.8h in high yield. There was no 
appreciable deuterium incorporation in this product, which can be attributed to this 
secondary source of acid. 

























In this study, ligand transfer of zirconocylcopentenes to boron followed by 
oxidation of the resulting organoboranes has been investigated. Conversion was strongly 
dependent on the boron reagent used with (cHex)2BCl giving the best results of the 
reagents screened and providing yields close to protonolysis of the zirconocycle. The 
process takes place regioselectively at the Csp3-Zr bond regardless of alkyne substitution 
and relative stereochemistry is conserved between protonation and oxidation products. 
The method produces 5- and 6-membered rings with a hydroxymethyl substituent 
available for further elaboration and constitutes a proof of concept for connecting the 
chemistry of relatively unreactive zirconocyclopentenes with that of organoboranes.46  
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Chapter 2: Cobalt-Mediated Oxidation of 4-Alkenols 
2.1  INTRODUCTION  
Tetrahydrofurans are found in a variety of natural products including 
Annonaceous acetogenins,47 polyether antibiotics48 and C-glycosides,49 inspiring 
numerous approaches to this heterocycle.50 Our interests in this area have focused on the 
acetogenins bullatacin (2.16) and squamotacin (2.17), which despite very similar 
structures (Figure 2.1) exhibit remarkable differences in cytotoxicity toward lung, renal 
and colon cancer cell lines (Table 2.1).51,52 Recent studies in this laboratory have focused 
on the effect of chain length between the bis-THF and butenolide subunits on biological 
activity, requiring a modular synthetic approach to analogs. Monoprotected bis-THF diol 
2.18 was chosen as a key precursor, allowing systematic introduction of different tether 
lengths (Scheme 2.1).  












Squamotacin (2.17)  
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Table 2.1 Cytotoxicity profiles of acetogenins 2.16 and 2.17 for lung, colon and renal 
cancer cell lines51 
   
 












2.2  PREVIOUS APPROACHES TO THE MONOPROTECTED BIS-THF 
Monoprotected bis-THF diol 2.18 has been used in previous syntheses of 
acetogenins and has been prepared in two distinct ways. Koert’s route to 2.18b (P = TBS) 
began with double alkylation of bromide 2.19 with acetylene followed by dissolving 
metals reduction of the internal alkyne to give trans alkene 2.20 (Scheme 2.2).53a 
Sharpless asymmetric dihydroxylation54 and tosylation of the resulting diol provided bis-
tosylate 2.21. Finally, hydrolysis of the acetonides followed by dual cyclization under 
basic conditions and monoprotection of the diol provided 2.18b.53b 
 
 Cytotoxicity (ED50, μg/mL) 
 A-549 (lung) HT-29 (colon) A-498 (renal) 
Bullatacin 2.44 x 10-6 >1 6.96 x 10-1 
Squamotacin 2.77 x 10-2 1.0 x 10-3 >1 
 30







    -33 °C
2. Na, NH3/THF
    -33 °C
O O
OO
















Wang and Shi described a more direct and efficient, three-step preparation of bis-
THF 2.18c (P = Bn) starting from trans-triene 2.22 (Scheme 2.3).55a,55b Sharpless 
asymmetric dihydroxylation of the internal double bond provided diol 2.23a, which was 
transformed to bis-THF diol 2.23b using Mukaiyama’s cobalt-mediated oxidative 
cyclization of bishomoallylic alcohols.56 Selective protection of one of the primary 
hydroxyls as a benzyl ether provided 2.18c. This attractive route to the bis-THF core 












t-BuOH:H2O (1:1), 0 °C Co(modp)2 (10 mol %)
TBHP, O2









2.3  ORIGIN OF THE COBALT OXIDATION OF BIS-HOMOALLYLIC ALCOHOLS 
In 1989, Mukaiyama described the aerobic peroxygenation of alkenes using 
triethylsilane and catalytic amounts of bis(1,3-diketonato)cobalt(II) complexes, providing 
triethylsilyl peroxides with Markovnikov regiochemistry (Table 2.1).57a-57c Modifying the 
conditions by employing i-PrOH as solvent/reductant provided hydration products under 
neutral conditions along with minor amounts of the corresponding ketones and alkanes 
(Table 2.3).58 Interestingly, when bis-homoallylic alcohols were subjected to similar 
conditions, a mixture of trans-methyltetrahydrofurans and trans-
hydroxymethyltetrahydrofurans was obtained. Optimization of conditions and catalyst 
screening effected a more selective reaction, providing exclusively the latter oxidative 
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2.4  OBJECTIVES OF THE CURRENT RESEARCH 
The reported high trans-selectivity (>95% dr) and relatively low catalyst loadings 
(20 mol %) for Mukayama’s protocol offer a promising complement to VO(acac)2/t-
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cis-THF isomer (~80-90% dr) and anti-specific formation of the two new C-O bonds due 
to a directed epoxidation/epoxide-opening mechanism.50a,59 However, cis/trans selectivity 
falls lower for unsubstituted alkenes. The Kennedy oxidation provides excellent trans-
selectivities and syn-stereospecific formation of the C-O bonds, but typically requires at 
least 50 mol % Re for best results.50a,60 
Despite the great potential of the Mukaiyma oxidation, Wang and Shi’s syntheses 
were the only reported applications when the current research began, a decade after 
Mukaiyama’s initial discovery. While two additional examples have since been described 
by Evans61 and Takahashi62 in separate syntheses of the acetogenin mucocin, one group 
of researchers has cited difficulty in reproducing Mukayama’s yields.63 Indeed, early 
attempts to recreate Mukaiyama’s results in this laboratory were similarly disappointing.  
As such, one goal of the current research was to determine the cause of these 
lower yields and improve the reliability of the method. Additionally, we were interested 
in substrate control of diastereoselectivity in these oxidations. The alkenols tested by 
Mukaiyama were exclusively α-substituted, providing the corresponding 2,5-disubstituted 
THFs. Therefore, a secondary objective of this work was to explore the scope of this 
reaction by determining the stereochemical outcomes and reaction efficiencies for other 
substitution patterns. 
2.5 RESULTS AND DISCUSSION 
2.5.1 Ligand and catalyst preparation 
The modp ligand and cobalt catalyst used for the cobalt catalyzed oxidation were 
prepared by modification of the original procedure (Scheme 2.4).64 Ethylmorpholine 
glyoxylate (2.24) was prepared in 96% yield by reaction of ethyloxalyl chloride with 
morpholine and NEt3. The reported 36% yield for KOtBu promoted condensation of 2.24 
 35
with pinacolone was improved to 78% by changing the reaction conditions from toluene 
at reflux to THF at rt and using AcOH instead of HCl for protonation. Additionally, 
Mukaiyama reported complexation of the ligand with CoCl2 under basic conditions. A 
previous researcher in this laboratory found that the CoII(modp)2 produced by this method 
gave low yields in the oxidation of bis-homoallylic alcohols. Suspecting competitive 
hydrolysis of the activated amide, the complexation procedure was altered by treating the 
ligand with CoII(2-ethylhexanoate) under neutral conditions to produce CoII(modp)2 
(2.26) in 95% yield. The CoII(modp)2 prepared in this way consistently gave yields for 
the oxidation comparable to those reported by Mukayama. 









































2.5.2 Substrate preparation 
A series of bis-homoallylic alcohols were prepared to determine the scope of the 
cobalt-mediated oxidation and the effect of substitution on diastereoselectivity. Substrates 
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2.27a-2.31a, exhibiting various alkene substitution patterns, were prepared by treatment 
of hydrocinnamaldehyde with the corresponding Grignard reagents (Scheme 2.5). 
2-Substituted alcohol 2.33a was prepared by benzylation of allyl dimethylmalonate, 
Krapcho decarboxylation and LiAlH4 reduction of the resulting methyl ester (Scheme 
2.6). 3-Substituted alcohol 2.37a was prepared by NaBH4 reduction of the corresponding 
aldehyde, which was obtained by Claisen rearrangement/decarboxylation of the trans-
cinnamyl alcohol adduct of  (E)-(carboxyvinyl)trimethylammonium betaine 2.39 
(Scheme 2.7).65  















2.28a, R1=Me, R2=R3=H (61%)
2.29a, R1=R2=H, R3=Et (54%)
2.30a, R1=R3=H, R2=Et (50%)
2.31a, R1=H, R2=R3=Me (42%) 
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Diols 2.23a and 2.41a were prepared by Cu(I)-catalyzed addition of allyl- and 
vinylmagnesium bromide to epoxide 2.4266 (Scheme 2.8).  Monoacetate 2.43a was 
obtained from 2.23a by condensation with triethylorthoacetate followed by hydrolysis of 
the resulting orthoester with AcOH/H2O (Scheme 2.9). Mono-THF 2.18a was prepared 
by cobalt-mediated oxidation of 2.43a followed by TBS ether protection of the resulting 
 38
alcohol and deprotection of the acetate with EtMgBr. Similarly, 2.45a was furnished by 
acetate deprotection (NaOH/MeOH) of the cobalt oxidation product of 2.43a. Finally, 
diol 2.46a was prepared in several steps from triflate 2.47.67 Monoallylation and 
hydrolysis of the acetonide gave diol tosylate 2.48, which after treatment with 
K2CO3/MeOH and TBS protection of the remaining alcohol, afforded epoxide 2.49. 
Copper-catalyzed addition of phenethylmagnesiumbromide followed by NBu4F 
deprotection of the TBS ether provided diol 2.46a. 
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73% 2.46a  
2.5.3 Evaluation of oxidation conditions 
The reaction conditions described by Mukaiyama included the use of molecular 
sieves one equivalent of t-BuOOH relative to the substrate and 20 mol % of the 
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Co(modp)2 catalyst. Indeed, no experiments without molecular sieves or with lower 
catalyst loadings were reported. The use of the t-BuOOH was ascribed to decreasing the 
induction period of the reaction by accelerating oxidation of CoII to CoIII. While this 
process and the subsequent oxidative cyclization of the substrate take place under the O2 
atmosphere of the reaction, Mukaiyama observed slightly lower yields without the use of 
t-BuOOH. As our intended use of this method in the synthesis of acetogenins and analogs 
was prior to diversification, we required large scale oxidations and hoped to streamline 
this method by reducing or eliminating potentially unnecessary components. 
Mukaiyama’s optimized conditions were reproduced using alkenol 2.27a as a 
model providing 2.27b in 81% yield (Table 2.4, entry 1). Visually, molecular sieves 
appeared to accelerate the conversion of CoII to CoIII as the reaction mixture changed 
colors from pink to green in seconds rather than hours without sieves. However, the yield 
of the reaction was unaffected by the exclusion of molecular sieves or lowering the 
catalyst loading to 5 mol % (entries 2 and 3). Further decreases in catalyst loading led to 
incomplete conversion, likely due to decomposition of the catalyst over time (entry 4).  
As reported, the yield decreased when no or a substoichiometric amount of t-
BuOOH was added to the reaction mixture (entries 5 and 6).  It was thought that if the 
role of the t-BuOOH was simply to accelerate oxidation of the cobalt complex, 
preactivation of the complex might be as effective and reduce the amount required. 
Oxidation of the CoII(modp)2 using t-BuOOH or H2O2 was found to be very rapid in 
CH2Cl2, providing a green complex isolable by flash chromatography. However, these 
















Entry Catalyst Loading Additives Catalyst Activation Yield 
1 20 mol % 4 Å MS 1 eq t-BuOOH in situ 81% 
2 10 mol % 1 eq t-BuOOH in situ 82% 
3 5 mol % 1 eq t-BuOOH in situ 80% 
4 2.5 mol % 1 eq t-BuOOH in situ 58%* 
5 10 mol % none n/a 58% 
6 10 mol % 0.2 eq t-BuOOH in situ 72% 
7 10 mol % none preactivated with t-BuOOH 68% 
* GC conversion 
2.5.4 Scope and limitations 
 The results of the cobalt-mediate oxidations of the substrates prepared above are 
summarized in Table 2.5 and Table 2.6. In agreement with Mukaiyama’s findings, cobalt-
mediated oxidation of bishomoallylic alcohol 2.27a provided the trans-2,5-substituted 
THF exclusively in 82% yield. Similarly, oxidation of 4-methylsubstituted 2.28a 
proceeded in 75% yield, affording a single diastereomer with the methyl and ring methine 
hydrogen trans to one another. Notably, attempts to oxidize 5,5-disubstituted substrate 
2.31a were unsuccessful even at elevated temperatures, providing only recovered starting 
material. 
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The oxidation of cis- and trans-alkenes 2.30a and 2.29a provided nearly identical 
mixtures of two diastereomers with little selectivity (71%, 1.2:1 dr; 53%,1.3:1 dr, 
respectively). Homoallylic cis- and trans- alkenes 2.50 and 2.51 were subjected to the 
reaction conditions as a control to determine if equilibration between the olefin isomers 
was occurring, and each alkene was recovered without any change. The 1H and 13C NMR 
spectra of these products matched those obtained from Swern oxidation/EtMgBr addition 
for alcohol 2.27b, indicating trans-THF rings were formed in both cases and that the 
stereocenter adjacent to the THF ring was epimeric. The relative stereochemistry between 
this stereocenter and the proximal ring stereocenter was determined for each diastereomer 
by characteristic 1H NMR chemical shifts.68  The scrambling of stereochemistry and 
nearly identical product distributions for the cis- and trans-alkenes preclude an epoxide-
forming/epoxide-opening process as in the case of vanadium oxidations and the 
cycloaddition mechanism proposed for the related Kennedy oxidation. A reasonable 
mechanistic explanation for this stereoselectivity is the formation of a stereochemically 
labile C-Co bond or radical at the position alpha to the ring followed by reaction with O2.  









 The effects of substitution at the allylic and homoallylic positions on reaction 
efficiency and diastereoselectivity were examined similarly. Oxidation of 2-substituted 
alcohol 2.33a, proceeded in high yield but moderate diastereoselectivity, providing a 
mixture of cis- and trans-THF products (83%, 1.7:1 dr). In contrast, 3-substituted 2.37a 
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afforded trans-THF 2.37b with a small amount of the cis-isomer (75%, 8:1 dr).  Relative 
stereochemistry for both entries was determined by comparison of 1H and 13C NMR 
spectra to a literature reference in a similar study of diastereoselectivity of vanadium 
oxidations.69 
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Table 2.6 Summary of oxidation results (cont’d) 

















































As mentioned previously, the bis-oxidation of diol 2.23a has been of considerable 
interest in this laboratory as a key reaction in a synthetic effort toward Annonaceous 
acetogenins and analogues. While this oxidation was reported previously,55 efforts to 
reproduce these results have consistently given significantly lower yields (78% vs 35%); 
undesirable at such an early stage of a multi-step synthesis and prior to diversification in 
the analog syntheses. Screening of reaction conditions including concentration (0.01M-
1M), temperature (40 °C-60 °C), catalyst loading (2.5%-20%) and the use of additives (4 
Å sieves, H2O, tBuOOH, BHT) have yielded modest improvement to 45%. Interestingly, 
despite Mukaiyama’s consistent use of sieves, addition of 1% (v/v) H2O was found 
beneficial, accounting for the majority of this improvement. However, larger quantities 
slowed the rate of reaction without further increase in yield. A slightly longer but more 
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efficient, stepwise strategy involving oxidations of 2.43a and 2.18a, both excellent 
oxidation substrates, has been developed as an alternative. 
Substrates 2.45a and 2.46a were prepared with the aim of gaining further insight 
into the cause of the low yields for the oxidation of 2.23a and aiding in optimization 
efforts. Diol 2.46a was chosen as a model for the first oxidative cyclization, to determine 
if 1,2-diols might simply be sensitive to the oxidation conditions. However, the resulting 
trans-THF diol 2.46b was produced in 74% yield. Similarly, mono-THF diol 2.45a the 
presumed intermediate in the oxidation of 2.23a, was subjected to the oxidation 
conditions and produced bis-THF 2.45b in 77% yield, indicating that the intermediate 
and the bis-THF product are stable under the reaction and workup conditions.  For 
additional comparison, diol 2.41a was subjected to similar oxidation conditions providing 
the fused bicyclic bis-THF 2.41b as a single diastereomer in 50% yield. The similarity of 
this yield to that for 2.23a provides support for the explanation that low yields in these 
bis-oxidations are simply artifacts of combined yields over two reactions. 
2.6 CONCLUSION 
 The stereoselectivity and efficiency of the cobalt-mediated oxidative cyclization 
of bis-homoallylic alcohols has been studied. Additionally, the synthesis of the 
Co(modp)2 complex used for this process has been optimized, providing a reliable 
catalyst from batch to batch. Oxidation of a 4-methylsubstituted alkenol proceeds with 
very high stereoselection, affording a THF product with the ring methine hydrogen and 
the methyl group in a trans relationship, while a 5,5-dimethylsubstituted alkenol failed to 
cyclize. Cis- and trans-bishomoallylic alcohols exhibit high selectivity for the trans-THF, 
but poor and nearly identical syn/anti selectivity. The oxidation of 2- and 3-substituted 
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alkenols occurs with moderate to good stereoselectivity with preference for cis- and 
trans-THF rings, respectively.  
Investigation into the low yield of a bis-oxidation relevant to acetogenin synthesis 
has demonstrated that 1,2-diols and THF-substituted alkenols behave typically in the 
oxidation and that the low yield of these bis-oxidations is likely due to the combined 
yield of the two reactions. 
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Chapter 3: Annonaceous Acetogenins 
3.1 INTRODUCTION 
 
Acetogenins from the Annonaceae family of plants (e.g. apple custard, soy sop) 
constitute a large class of natural products, many of which exhibit potent biological 
effects including antitumoral, antimalarial and pesticidal acitivties.47 Currently, over 400 
compounds have been reported in this class since uvaricin was first isolated in 1982. 
Acetogenins are believed to originate from C32/C34 fatty acids that combine with a 2-
propanol group to form a γ-lactone and typically contain one or more THF, THP or 
epoxide rings and hydroxyl groups in various postitional and stereochemical 
arrangements along the chain (Figure 3.1). In particular, the extremely high cytotoxicity 
of certain acetogenins toward various tumor cell lines, including multi-drug resistant 
(MDR) cancer cells has inspired investigations into the mode of action70 for acetogenins 
as well as structure-activity relationship (SAR) studies71 and numerous partial and total 
synthetic efforts.72 
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3.2 PROPOSED MODES OF ACTION 
 
3.2.1 Mitochondrial complex I inhibition 
 
The primary source of biological activity for the acetogenins involves interaction 
with membrane bound mitochondrial complex I (NADH:ubiquinone oxidoreductase).70 It 
is believed that these compounds interfere with the terminal electron transfer step 
between an Fe-S cluster and ubiquinone.73 As a result, the cross-membrane proton 
gradient created by complex I during NADH reduction of ubiquinone and the electron 
transfer necessary for respirative reduction of O2 to H2O are inhibited, significantly 
reducing ATP levels. The exact nature of the interaction with complex I and the location 
of the binding site have yet to be determined, but a current model is depicted below 
(Figure 3.2). McLaughlin has proposed that the hydrophilic central region of acetogenins 
acts as an anchor to the glycerol backbone of phosphatidylcholine at the surface of the 
membrane, allowing the alkyl-tethered lactone ring to diffuse into the membrane interior 
and interact with the binding site of the enzyme.74 
Figure 3.2 McLaughlin’s model for acetogenin inhibition of mitochondrial complex I 
          Complex I 






Ultimately, complex I inhibition starves the cell of ATP, inhibiting cell growth 
and disturbing cell timing, inducing apoptosis. Significantly, this ATP depletion has been 
linked to the efficacy of acetogenins against MDR cancer cell lines.71c,75 The resistance 
developed by these cells typically results from increased expression of a glycoprotein 
which forms a channel in the cell membrane that actively exports antitumor agents.76 As 
additional ATP is required for this extrusion process, the ATP starvation induced by 
acetogenins makes these cells especially susceptible (~ 5 x non-MDR). For example, 
bullatacin was shown to be cytotoxic to MDR human mammary adenocarcinoma cells, 
while cytostatic to the parent non-MDR cell line.75 
 
3.2.2 Inhibition of ubiquinone-linked NADH oxidase 
A distinct, but closely related mode of action is the inhibition of membrane-bound 
NADH oxidase activity required for substrate-level phosphorylation.70c This secondary 
mechanism is believed to impart additional selectivity for cancerous cells over normal 
cells and differential selectivity between cancer cell lines. Cancerous cells generally 
express these oxidases throughout their plasma membranes to accommodate the high 
energy demand, while normal cells generally contain much fewer. 
 
3.3 STRUCTURE ACTIVITY RELATIONSHIPS 
 
3.3.1 Inhibition studies 
 Several papers outlining the critical elements for strong inhibition of complex I 
have been reported using various acetogenins. An early report by Alfonso concluded that 
acetogenins containing adjacent bis-THFs are more potent inhibitors of complex I than 
non-adjacent bis-THF compounds, which are more active than mono-THF substrates.71j 
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Additionally, the authors indicated that the presence of a hydroxyl at C-4 and the 
stereochemical configurations of the bis-THF and the flanking hydroxyl groups were 
significant. Specifically, compounds having erythro/trans/threo/trans/threo 
stereochemistry (e.g. bullatacin) provided the highest activities. However, Miyoshi and 
coworkers have downplayed the importance of each of these structural features, with 
acetogenins having various stereochemical arrangements, non-adjacent bis-THF or mono 
THF rings, and examples lacking a hydroxyl at C-4 providing similar inhibition levels 
(Table 3.1).71g,71k,71m  Additionally, these researchers found that the α,β-unsaturated 
lactone present in most acetogenins was not critical for inhibition as gigantetroninone, 
containing an isomeric keto-lactone, provided a result comparable to bullatacin. 
Table 3.1 Acetogenin SAR study of NADH oxidase inhibition 
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The IC50 value is the molar concentration required to decrease the NADH oxidase 




Table 3.2 Acetogenin SAR study of NADH oxidase inhibition (cont’d) 
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2.9 
The IC50 value is the molar concentration required to decrease the NADH oxidase 
activity of bovine heart submitochondrial particles by half 
 
One structural feature that has shown a definitive impact on inhibition is the 
length of the alkyl spacer between the central THF region and the γ-lactone.71c,71g,71k,71m 
The difference in activity between parviflorin and longimicin C and between annonacin 
and goniothalamicin, which differ only in tether length, illustrate this effect. That is, a 
small decrease in spacer length results in a marked decrease in potency. This could be 
attributed to preventing the active lactone moiety from penetrating deep enough into the 
membrane to reach the active site of complex I. However, McLaughlin has investigated 
the membrane conformations of a set of aceteogenins possessing tether lengths of 13, 11, 
and 9 carbons by 1H NMR NOE’s and DSC, elucidating a more subtle effect.74 The 9-
carbon tether actually caused the tether to point downward, with the lactone residing 
around the midplane of the bilayer while the 13- and 11-carbon chains allowed the 
lactone to diffuse laterally through the midchain area of the upper layer. 
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3.3.2 Cytotoxicity Studies 
Although complex I inhibition is believed to be the primary mode of action and 
many acetogenins are potent inhibitors, cytotoxicity against tumor cell lines varies 
widely, and it has been difficult to reliably correlate inhibition levels with cytotoxicity. 
Of course, assays using intact cells are more complicated than the inhibition studies 
which use submitochondrial particles. Additional factors such as membrane transport, 
intracellular transport and metabolic inactivation require consideration in cytotoxicity 
studies and the picture is further muddled by cell line specificity.71m Consequently, 
attempts to formulate SARs from these cytotoxicity profiles is far more challenging. 
Interestingly, the role of the chain length between the THF core and the 
butenolide on inhibition does correlate well to anti-tumor activity. Squamotacin only 
differs from bullatacin in that the bis-THF core is shifted two carbons closer to the 
butenolide. While McLaughlin’s conformational studies might suggest that an 11-carbon 
tether is sufficiently long to allow lateral diffusion, squamotacin showed remarkably 
different activity than bullatacin (Table 3.3).51 
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Table 3.3 Cytotoxicity dependence on tether length 
 ED50 (μg/mL) 





(  )8 (  )9
 
Bullatacin 





(  )10 (  )7
 
Squamotacin 
2.77 x 10-2 >1 1.0 x 10-3 
A-549 = human lung carcinoma; MCF-7 = human mammary adenocarcinoma; HT-29 = 
human colon adenocarcinoma 
 
3.4 OBJECTIVE OF THE CURRENT WORK 
The long term objective of the current research is to help clarify the SAR picture 
for the cytotoxicity of acetogenins. Despite the many acetogenins that have been isolated, 
defining trends from biological assays of natural products is limited by lack of control 
over nature’s variation. Synthesis should allow more systematic evaluation of the features 
necessary for activity by limiting the variables between structures and filling in gaps of 
compounds unavailable from nature. Intrigued by the disparity in activity between 
bullatacin and squamotacin, we decided to further explore the effect of tether length 
between the bis-THF core and the butenolide further by synthesizing analogs with longer 
and shorter tethers, respectively. As such, the goal of the current research was 
implementation of a concise, modular synthesis of unnatural acetogenins recently 
developed in our laboratory.77  
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3.5 PREVIOUSLY REPORTED SYNTHESES OF BULLATACIN 
Largely due to their exciting biological effects, a large number of synthetic efforts 
towards acetogenins have been reported and comprehensive reviews are available. With 
our research efforts focused on preparing analogs of bullatacin and squamotacin, an 
overview of previous syntheses of these acetogenins will be presented here. 
 
3.5.1 Sasaki’s synthesis of bullatacin 
The first total synthesis of bullatacin was reported by Sasaki, beginning with 
acetonide-protected D-diethyl tartrate 3.52.78 Wadsworth-Emmons homologations and 
appropriate reductions set up a double Sharpless asymmetric epoxidation,79 which 
provided bis-epoxide 3.53 after PNB protection. Subsequent Lewis acid-catalyzed ketal 
cleavage and intramolecular epoxide-opening provided bis-THF 3.54. Mono-mesylation 
and basic hydrolysis of the PNB esters afforded epoxy diol 3.55, which was treated with 
an α-sulfonylanion to introduce the chain that ultimately would contain the butenolide. 
After desulfonation and selective tosylation of the primary hydroxyl, epoxide 3.57 was 
produced under basic conditions. Copper-catalyzed addition of the appropriate Grignard 
followed by MOM protection produced advanced intermediate 3.58. Following TBS 
deprotection and methyl ester formation, a crossed aldol reaction with an aldehyde 
derived from (S)-(-)-methyl lactate furnished the butenolide subunit. Deprotection of the 
MOM ethers provided bullatacin.  
One advantage of Sasaki’s approach was its use of tartaric acid, a highly 
enantioenriched starting material, to set the stereochemistry of the core bis-THF. The 
most common alternative, Sharpless asymmetric dihydroxylation, can provide high 
enantiomeric excesses (~95%),54 but even a small contamination in optical purity might 
further complicate cytotoxicity assays. Sasaki’s synthesis also took great advantage of the 
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C-2 symmetry of the tartrate derivatives, allowing for bidirectional synthesis. However, 
from the perspective of making analogs with varying tether lengths, a drawback of this 
route was the formation of the butenolide after the alkyl spacer was introduced. A more 
modular approach, where the spacer and butenolide could be introduced separately would 
be more desirable for our purposes. 































































3.5.2 Keinan’s synthesis of bullatacin and squamotacin 
Keinan’s described a “naked” carbon skeleton strategy for the synthesis of 
bullatacin, where all of the oxygenated stereocenters were generated by appropriate 
oxidation at sites of unsaturation.80 Selective Sharpless asymmetric dihydroxylation of 
the trans-alkene of dienyne 3.59 provided lactone 3.60. The THF rings were then formed 
stepwise by Re2O7 oxidation of the corresponding cis-bishomoallylic alcohols. 
Tranformation of the lactone into a Wittig salt and condensation with aldehyde 3.63 
assembled the bullatacin skeleton. Reduction of the resulting alkene and deprotection of 
the MOM ethers provided bullatacin. A nearly identical approach was used by Keinan in 
the synthesis of squamotacin.81  
While Keinan’s route is elegantly simple, the nature of this “naked” carbon 
skeleton strategy makes divergence difficult. That is, the majority of the steps take place 
after the carbon skeleton, the feature we wish to vary, has been assembled. Also, as 
mentioned in the previous section, the route is limited by the level of enantiopurity 
attainable using the asymmetric dihydroxylation method. 
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3.5.3 Hoye’s synthesis of bullatacin 
Hoye employed a similar approach to Keinan’s, beginning with Sharpless 
dihydroxylation of diene 3.64 followed by acetonide formation to give 3.65.82 Tosylation 
followed by basic cleavage of the lactone provided an intermediate epoxide, which 
underwent cyclization upon hydrolysis of the acetonide to give THF lactone 3.66. 
Reduction of the lactone and Wittig olefination of the lactol provided allylic alcohol 3.67 
which was subjected to Sharpless epoxidation. The resulting epoxide underwent 
cyclization to form the second THF ring under the reaction conditions and the resulting 
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diol was converted to epoxide 3.68 in a three step process. Mitsunobu inversion83 of the 
alcohol followed by addition of the lithium anion of TMS-acetelyne and desilylation of 
the alkyne provided alkyne 3.69. Pd-catalyzed cross coupling with vinyl iodide 3.70 
followed by selective reduction of the resulting enyne with Wilkinson’s catalyst and silyl 
deprotection produced bullatacin.  
As the approaches are strategically similar, the advantages and disadvantages of 
Keinan’s synthesis apply here. While an effective synthesis of bullatacin, the use of 
asymmetric dihydroxylation to set the core stereochemistry and the lack of flexibility 
make it undesirable for our purposes. 









































3.5.4 Roush’s synthesis of bullatacin 
Roush recently reported a synthesis of bullatacin utilizing [3+2] annulations of 
aldehydes with chiral allylsilanes.84,85 Cyclization of benzyloxyacetaldehyde with 
allylsilane 3.71, followed by removal of the benzyl group and oxidation provded 
aldehyde 3.72. A second [3+2] annulation formed the second THF ring and assembled 
the bullatacin skeleton. One-pot protiodesilylation of the C-Si bonds and cleavage of the 
TBS ethers provided 3.74, which was transformed into bullatacin in a 4-step sequence.  
Roush’s synthesis of bullatacin was very direct but too linear for our purpose. 
Formation of the butenolide at the end of the synthesis would add these steps to each 







































Chapter 4: Synthesis of Acetogenin Analogs 
4.1 RETROSYNTHETIC ANALYSIS 
 With a modular synthesis of bullatacin and squamotacin analogs in mind, our 
retrosynthetic analysis divided the basic structure into four subunits: the alkyl chain, the 
bis-THF core, the alkyl tether and the butenolide. We envisioned using aldehyde 
additions to connect the alkyl groups to the bis-THF and acetylide addition to epoxy 
butenolide 4.75 to complete the acetogenin skeleton (Scheme 4.1 and Scheme 4.2). A 
major benefit of this approach is that the components we wished to vary, the alkyl chain 
and the tether, could either be purchased or are readily available.  
As described in Chapter 2, a suitably protected bis-THF diol could be attained 
using Mukaiyama’s oxidative cyclization of diol 2.23a. In contrast to Wang and Shi’s use 
of asymmetric dihydroxylation, we chose to prepare this diol by allylation of bis-epoxide 
2.42, conveniently available from (D)-tartaric acid.66  Finally, previous research in this 
laboratory77 has offered convenient access to epoxy butenolide 4.75 by selective 
alkylation of epichlorohydrin with White’s lactone 4.76.86  
 











































4.2 SYNTHESIS OF THE BIS-THF CORE 
Although individual steps of the bis-THF synthesis were described in Chapter 2, a 
brief overview is presented here (Scheme 4.3). Copper-catalyzed Grignard allylation of 
bis-epoxide 2.42 provided diol 2.23 in 81% yield. The diol was treated with 
triethylorthoacetate and acidic hydrolysis of the resulting orthoester gave a 99% yield of 
monoacetate 2.43a. Cobalt-mediated oxidation of 2.43a provided mono-THF 2.43b, 
which was protected as a TBS ether to give 4.77 in 76% yield over two steps. 
Deprotection of the acetate with EtMgBr and cobalt-mediated oxidative cyclization 
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afforded monoprotected bis-THF diol 2.18b in 78% yield. Swern oxidation provided a 
96% yield of aldehyde 4.78, which was used to introduce the first alkyl side chain.  
 

























4.3 INTRODUCTION OF THE ALKYL CHAIN 
Stereoselective addition to α-chiral aldehydes has been the focus of intense study 
by several groups and successful approaches using chelation control or the Felkhin-Anh 
model have been developed. However, stereoselective addition to α-THF aldehydes has 
historically been difficult.87 A common remedy for this issue has been to perform an 
unselective addition, oxidize and reduce the ketone with L-Selectride™ to provide the 
threo isomer.88 While the erythro isomer can be obtained by subsequent Mitsunobu 
inversion followed by hydrolysis of the ester, this process comprises 5 synthetic steps and 
detracts from overall efficiency. Bullatacin and squamotacin require erythro 
sterechemistry at the hydroxyl joined to the terminal alkyl chain, and the initial synthesis 
of the natural products in this laboratory utilized this indirect and somewhat inefficient 
route. The goal of preparing multiple analogs prompted efforts in our laboratory to 
achieve a more direct addition.  
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Another researcher in our laboratory screened several chelation-controlled and 
reagent-controlled additions of alkyl metals to bis-THF aldehyde 4.78, which consistently 
gave low to moderate levels of selectivity.77 He discovered that acetylides generally gave 
better selectivities than aliphatic organometallics. In particular, Ti-acetylides, generated 
from the corresponding lithium acetylide and ClTi(OiPr)3, gave excellent stereoselectivity 
for the desired erythro isomer. Treatment of aldehyde 4.78 with the Ti-acetylide of 1-
decyne provided 4.79 as an inseparable mixture of isomers in 82% yield (erythro/threo: 
10:1; Scheme 4.4). Hydrogenation provided a separable mixture of erythro/threo isomers 
4.80a and 4.80b in 85% yield, along with 10% of the reductive isomerization product, 
ketone 4.81. 






















4.4 THE TETHER  
4.4.1 Synthesis of the tether 
For bullatacin and squamotacin, the hydroxyl on the tether side of the THF core is 
threo relative to the adjacent THF stereocenter, so we chose to use the non-selective 
addition/oxidation/L-Selectride™ reduction protocol to achieve the correct 
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stereochemistry. For this, we required a tether precursor with a halogen for Grignard 
formation and addition to a THF aldehyde at one end, and a suitably protected (TMS) 
alkyne at the other terminus for addition to the epoxy butenolide. Many such compounds 
have been reported in the literature and are most easily prepared by conversion of the 
corresponding alcohols to the halides.89 The alcohols are available by persilylation of the 
appropriate ω-hydroxyalkynes followed by acidic hydrolysis of the TMS ether. A few of 
these ω-hydroxyalkynes are commercially available while others can be prepared by 
zipper isomerization of commercially available internal alkynes.  
The synthesis of tether precursor 4.82 illustrates this approach (Scheme 4.5). 
Silylation of 1-hydroxy-10-undecyne (4.83) with an excess of n-BuLi and TMSCl 
followed by hydrolysis of the TMS ether provided a 90% yield of the hydroxy TMS-
alkyne.  Mesylation of the alcohol and substitution with LiBr provided 4.82 in 91% yield 
over two steps. 
 
Scheme 4.5 Synthesis of tether precursor 4.82 
 




3. LiBr, acetone 4.824.83
82%  
 
4.4.2 Incorporation of the tether 
Prior to addition of the tether, the free alcohol of 4.79a was protected as a benzyl 
ether and the TBS ether was converted to aldehyde 4.84 by NBu4F deprotection and 
Swern oxidation in 87% yield over three steps (Scheme 4.6). Subsequent addition of the 
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Grignard reagent formed from 4.82 provided a separable mixture of erythro/threo 
diastereomers 4.85a and 4.85b in 79% yield (erythro/threo: 1:2). The desired threo 
isomer 4.85b was isolated and used for the remainder of the synthesis. Desilylation of the 
TMS-alkyne using K2CO3/MeOH followed by benzylation of the alcohol afforded a 79% 
yield of terminal alkyne 4.86, which could be used in the addition to epoxy butenolide 
4.75. 
 
Scheme 4.6 Incorporation of the tether 
 






























4.5 SYNTHESIS OF THE EPOXY BUTENOLIDE 
As previously mentioned, another researcher in our laboratory prepared epoxy 
butenolide 4.75 in three steps from White’s lactone 4.76 (Scheme 4.7).77 Chemoselective 
alkylation of the lithium enolate of 4.76 with R-epichlorohydrin in the presence of BEt3 
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provided chlorohydrin 4.87 in 86% yield.  Cyclization to the epoxide with NaH and 
oxidative elimination furnished the epoxy lactone 4.75 in 70% yield over two steps.  
 




















4.6 FINAL ASSEMBLY OF THE TETHER-ELONGATED BULLATACIN ANALOG 
With terminal alkyne 4.86 and epoxy butenolide 4.75 in hand, the acetogenin 
skeleton was nearly complete. Addition of the lithium acetylide of 4.86 to 4.75 in the 
presence of BF3•OEt2 was found to be extremely moisture sensitive at the small scales 
used, consistently returning unreacted starting material. Predrying THF solutions of the 
alkyne and the epoxide with activated 4Å MS proved insufficient to remedy this issue. 
However, extended drying of the startin materials in vacuo allowed addition to take 
place, affording advanced intermediate 4.88 in 51% yield (78% BRSM; Scheme 4.8). 
Deprotection of the benzyl ethers with DDQ90 and diimide reduction of the internal 






Scheme 4.8 Completion of acetogenin analog 4.89 
1. n-BuLi
2. 4.75, BF3•OEt2





















4.7 22-DEOXY ANALOG OF SQUAMOTACIN 
Prior to the innovation of the Ti-acetylide addition, an alternative solution to the 
problematic erythro stereochemistry of the hydroxyl on the terminal alkyl chain side of 
the THF was explored. We envisioned that a set of deoxy analogs lacking this 
stereocenter, while potentially compromising activity, might still provide insight into the 
effect of the tether length. As many of the reactions used in the synthesis of the tether-
elongated analog of bullatacin overlaps, a brief summary of the synthesis of a 22-
deoxysquamotacin is presented here. 
 
4.7.1 Introduction of the terminal alkyl chain  
The terminal alkyl chain of the deoxy analog was introduced by Wittig olefination 
of aldehyde 4.78,91 providing alkene 4.90 in 81% yield (Z/E: >20:1), which could be 
reduced along with the alkyne at the end of the synthesis (Scheme 4.9). Deprotection of 
the TBS ether with NBu4F and oxidation under Swern conditions provided aldehyde 4.91 
in 87% yield.  
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Scheme 4.9 Formation of the deoxy analog precursor by Wittig olefination 
O O
OTBS















4.7.2 Synthesis of the tether precursor 
The synthesis of tether precursor 4.92 began with zipper isomerization of 1-
hydroxy-3-heptyne to give terminal alkyne 4.94 in 69% yield (Scheme 4.10). 
Persilylation of 4.94 with n-BuLi and TMSCl and hydrolysis of the TMS ether provided a 
90% yield of TMS alkyne 4.95. Conversion of the alcohol to the mesylate and 
displacement with LiBr provide bromo alkyne 4.92 in 91% yield.  
 
















Addition of the Grignard reagent formed from 4.92 to aldehyde 4.91 provided a 
separable mixture of diastereomers 4.96a and 4.96b in 67% overall yield (threo:erythro 
2:1, Scheme 4.11). TPAP oxidation of the mixture and L-Selectride™ reduction of the 
ketone gave a 77% yield of 4.96a and 4.96b (threo:erythro 10:1). The desired threo 
isomer 4.96a was isolated at this stage and used in the remainder of the synthesis. 
 



















4.9777% (th/er 10:1)  
 
 
4.7.3 Completion of 22-deoxysquamotacin 
Desilylation of alkyne 4.96a using K2CO3/MeOH followed by benzylation of the 
alcohol gave terminal alkyne 4.97 in 89% yield over two steps (Scheme 4.12). The 
lithium acetylide of 4.97 was then added to epoxy butenolide 4.75 in the presence of 






















(89% BRSM) 4.98  
 
Attempted DDQ deprotection of the benzyl ether of 4.98 produced a meager 23% 
yield of the desired product 4.99, presumably caused by competive oxidation of the 
allylic ether of the terminal alkyl chain (Scheme 4.13). As a solution to this, the diimide 
reduction was performed prior to debenzylation, providing 22-deoxysquamotacin in 
86% yield over two steps. 





























The synthesis of bullatacin analogs recently developed in our laboratory has been 
successfully applied to two new derivatives, C-14 tether 4.89 and 22-deoxysquamotacin. 
As our objective was to study the effects of tether length on biological activity, these and 
additional bullatacin analogs with tether lengths of 10, 11 and 12 carbons have been 
prepared by another researcher in our laboratory77 and submitted to NIH for testing. 
Additionally, synthetic bullatacin (C-13) and squamotacin (C-9) have been prepared and 






CHAPTER 5: EXPERIMENTAL PROCEDURES 
 
5.1 GENERAL PROCEDURES 
 
All reactions were run under an atmosphere of nitrogen or argon unless specified 
otherwise. Flasks were oven or flame-dried and allowed to cool in a desiccator prior to 
use. A solution of anhydrous tert-butylhydroperoxide (TBHP) in isooctane was prepared 
according to the previously described procedure Solvents and reagents were purified by 
standard methods.92
 
Thin-layer chromatography (TLC) was performed on EM 250 
Kieselgel 60 F254 silica gel plates. The plates were visualized by staining with I2 on 
silica, CAM,79 or potassium permanganate. GC analyses were performed on a Hewlett-
Packard 5890 Series II instrument equipped with an Econocap column (Altech, 15 m x 
0.53 µm) and FID detector.  
The 1H and 13C NMR data was obtained on a Varian Unity Plus 300 or a Varian 
INOVA 400 or 500 spectrometer. For 1H NMR, chemical shifts are reported in parts per 
million (ppm) downfield from tetramethylsilane and are, in all cases, referenced to the 
residual proton resonance peaks: δ 7.24 for CHCl3. The 13C NMR chemical shifts were 
reported in ppm relative to the center peak of the solvent multiplet: δ 77.0 (t) for CDCl3. 
13C NMR spectra were routinely run with broadband 1H decoupling. NOE differences 
were determined using a double pulsed field gradient spin echo sequence (mixing time = 
800 msec) and values are reported adjacent to the enhanced hydrogen(s). Infrared spectra 
were obtained on a Nicolet AVATAR 360 FTIR. HRMS (CI) were made with a VG 
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analytical ZAB2-E instrument.  Where appropriate, descriptions of signals include broad 
(br), apparent (app) and multiplet (m).  
Compounds 1.3,38 1.7,93 1.8a,40 1.9a,94 1.15a,40 2.29a,95 2.33a,96 2.37a,97 2.42,66 
2.47,67 4.8298 and 4.9289 have been prepared previously. 





4,4-Bis(methoxymethyl)oct-1-en-6-yne (1.1a ).  To a 0 °C THF (30 mL) solution of 1.3 
(5.4 g, 30 mmol) was added n-BuLi (13 mL, 2.53 M, 33 mmol) dropwise.  After 30 min, 
MeI (2.3 mL, 36 mmol) was added dropwise to the solution, the reaction mixture was 
stirred an additional 1 h, and then allowed to warm to rt. After stirring 10 h at rt, a 
solution of NH4Cl (20 mL, sat’d) was added and the layers were separated.  The aqueous 
phase was extracted with ether and the combined layers were washed with Na2S2O3 (20 
mL, 10%) brine (50 mL), dried (MgSO4), filtered and concentrated in vacuo.  The 
resulting liquid was purified by vacuum distillation (62-65 °C, 0.3 mm Hg) to give the 
title compound as a clear colorless oil (5.2 g, 27 mmol, 89%): Rf 0.33 (5% 
EtOAc/hexanes); IR (thin film) ν  3075, 1639, 1109 cm-1; 1H NMR (400 MHz, CDCl3) δ 
5.77 (ddt, J = 9.9, 17.4, 7.5 Hz, 1H), 5.10-5.01 (m, 2H), 3.30 (s, 6H), 3.22 (d, J = 13.0 
Hz, 2H), 3.19 (d, J = 13.0 Hz, 2H), 2.14-2.08 (m, 4H), 1.77 (t, J = 2.6 Hz); 13C NMR 
(100 MHz, CDCl3) δ 134.1, 117.7, 77.2, 75.5, 74.4, 59.2, 41.8, 36.2, 22.2, 3.5; HRMS 






4,4-Bis(methoxymethyl)-7-trimethylsilylhept-1-en-6-yne (1.2a). To a 0 °C THF (30 
mL) solution of 1.3 (5.4 g, 30 mmol) was added n-BuLi (13 mL, 2.53 M, 33 mmol) 
dropwise.  After 30 min, Me3SiCl (4.5 mL, 36 mmol) was added dropwise to the canary 
yellow solution, the reaction mixture was stirred an additional h, and then allowed to 
warm to rt. After stirring 10 h at rt, a solution of NH4Cl (20 mL, sat’d) was added and the 
layers were separated.  The aqueous phase was extracted with EtOAc and the combined 
layers were washed with brine (50 mL), dried (MgSO4), filtered (Celite), and 
concentrated in vacuo.  The resulting liquid was purified by vacuum distillation (80-83 
°C, 0.25 mm Hg) to give the title compound as a clear colorless oil (6.48 g, 26 mmol, 
86%): Rf 0.35 (2.5% EtOAc/hexanes); IR (thin film) ν 3076, 2174, 1653, 1250, 1110 
cm-1; 1H NMR (400 MHz, CDCl3) δ 5.77 (ddt, J = 9.9, 17.10, 7.5 Hz, 1H), 5.10-5.01 (m, 
2H), 3.30 (s, 6H), 3.22 (d, J = 12.3 Hz, 2H), 3.20 (d, J = 12.3 Hz), 2.18 (s, 2H), 2.13 (d, J  
= 7.5 Hz), 0.13 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 133.9, 118.0, 104.2, 86.6, 74.3, 







4,4-Bis(methoxymethyl)-7-phenylhept-1-en-6-yne (1.4a).  Pd(PPh3)2Cl2 (0.51 g, 0.73 
mmol) and CuI (0.28 g, 1.5 mmol) were added to degassed NEt3 (24 mL, 173 mmol) at rt. 
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To the resulting mixture was added 1.3 (4.37 g, 24 mmol).  After 30 min, THF (20 mL) 
was added and the reaction mixture was stirred for 3 h.  The reaction mixture was 
concentrated, and the solid residue was extracted with Et2O and the extracts were filtered 
through a SiO2 plug using Et2O for elution.  Concentration and purification of the 
resulting liquid by flash chromatography on SiO2 0.25% EtOAc/hexanes) provided the 
title compound as a light yellow liquid (5.88 g, 23 mmol, 95%): Rf 0.32 (2.5% 
EtOAc/hexanes); IR (thin film) ν 3074, 1110, 756, 691 cm-1; 1H NMR (400 MHz, CDCl3) 
δ 7.43-7.38 (m, 2H), 7.32-7.25 (m, 3H), 5.85 (ddt, J = 7.5, 9.9, 17.1 Hz, 1H), 5.17-5.08 
(m, 2H), 3.36 (s, 6H), 3.33 (d, J = 13.0 Hz, 2H), 3.31 (d, J = 13.0 Hz, 2H), 2.42 (s, 2H), 
2.24 (d, J = 7.52 Hz, 2H); 13C NMR(100 MHz, CDCl3) δ 133.9, 131.5, 128.2, 127.5, 
124.0, 118.1, 87.0, 82.5, 74.5, 59.3, 42.2, 36.4, 22.9; HRMS m/z 259.1699 (calc’d for 




3-Benzyloxyhept-1-en-6-yne (1.100). To a suspension of NaH (0.31 g, 94%, 12 mmol) 
in DMF (11 mL) at 0 °C, was added 1.7 (1.20 g, 11 mmol) dropwise.  After 10 min 
benzyl bromide (1.45 mL, 12 mmol) was added dropwise, the reaction mixture was 
stirred for 1 h, and poured into a solution of NH4Cl (25 ml, sat’d). The resulting mixture 
was extracted with hexanes and the combined organic layers were washed with water (2 x 
20 mL) and Na2SO3 (20 mL, 10%), dried (MgSO4), filtered and concentrated in vacuo. 
Purification of the residue by flash chromatography on SiO2 (elution gradient: hexanes to 
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2.5% EtOAc/hexanes) provided the title compound as a clear, colorless liquid (1.39 g, 7.0 
mmol, 63%): Rf 0.36 (2.5% EtOAc/hexanes); IR (thin film) ν 3300, 3069, 3031, 1072 
739, 697 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.42-7.27 (m, 5H), 5.78 (ddd, J = 7.4, 10.3, 
17.4 Hz, 1H), 5.35-5.31 (m, 1H), 5.30-5.27 (m, 1H), 4.64 (d, J = 11.7 Hz, 1H), 4.40 (d, J 
= 11.7 Hz, 1H), 3.95 (ddd, J = 5.4, 7.4, 7.7 Hz, 1H), 2.44-2.25 (m, 2H), 1.96 (t, J = 2.8 
Hz, 1H), 1.95-1.70 (m, 2H); 13C NMR (75 MHz, CDCl3) δ 138.5, 138.2, 128.3, 127.7, 





3-Benzyloxyoct-1-en-6-yne (1.5a).  To a THF (10 mL) solution of benzyl ether 1.100 
(1.34 g, 6.7 mmol) cooled to 0 °C was added n-BuLi (3.1 mL, 2.56 M, 8.0 mmol) 
dropwise.  After 30 min, MeI (0.63 mL, 10 mmol) was added and the reaction mixture 
was stirred an additional 1 h and then poured into a stirred solution of NH4Cl (30 ml, 
sat’d). The layers were separated and the aqueous phase was extracted with EtOAc.  The 
combined extracts were washed with Na2SO3 (20 mL, 10%) and brine (30 mL), dried 
(MgSO4), filtered and concentrated in vacuo. The resulting oil was purified by flash 
chromatography on SiO2 (elution gradient: hexanes to 2.5% EtOAc/hexanes) provided 
the title compound as a clear, colorless liquid (1.22 g, 5.7 mmol, 85%): Rf 0.39 (2.5% 
EtOAc/hexanes); IR (thin film) ν 3031, 1070, 736, 698 cm-1; 1H NMR (400 MHz, CDCl3) 
δ 7.36-7.21 (m, 5H), 5.78-5.65 (m, 1H), 5.28-5.18 (m, 2H), 4.57 (dd, J = 2.1, 12.0 Hz, 
 78
1H), 4.35 (dd, J = 1.7, 12.0 Hz, 1H), 3.87 (ddd, J = 6.2, 6.2, 6.2 Hz, 1H), 2.30-2.13 (m, 
2H), 1.85-1.58 (m, 2H), 1.74 (t, J = 2.4 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 138.6, 
138.4, 128.3, 127.7, 127.4, 117.4, 79.1, 78.6, 45.7, 40.2, 13.7, 14.9, 3.4; HRMS m/z 






A THF (20 mL) solution of p-chlorophenylacetylene (2.06 g, 15 mmol) was cooled to 0 
°C and n-BuLi (5.9 mL, 2.71 M, 16 mmol) was added dropwise.  The acetylide solution 
was added dropwise to a 0 °C THF (15 mL) solution of aldehyde 1.11 (2.04 g, 18 mmol) 
via cannula. After 1 h the ice bath was removed and the reaction mixture was stirred 2 h 
at rt.  Following cannular addition of a solution of TBSCl in THF (10 mL), the reaction 
mixture was heated at reflux for 11 h. Afer cooling to rt, NH4Cl (20 mL, sat’d) was added 
and the mixture was stirred for 5 min.  The layers were separated and the aqueous layer 
was extracted with EtOAc. The combined extracts were washed with water (20 mL) and 
brine (20 mL), dried (MgSO4), filtered and concentrated.  Vacuum distillation (162-165 0 
°C, 0.25 mm Hg) of the liquid provided the title compound as a clear, colorless liquid 
(3.89 g, 11 mmol, 71%): Rf 0.65 (hexanes); IR (thin film) ν  3076, 1640, 1257, 1091, 837 
cm-1; 1H NMR (300 MHz, CDCl3) δ 7.39-7.27 (m, 4H), 5.88 (dddd, J = 7.4, 7.4, 9.22, 
17.9 Hz, 1H), 5.13-5.04 (m, 2H), 4.26 (s, 1H), 2.27-2.12 (m, 2H), 1.01 (s, 3H), 1.00 (s, 
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3H), 0.97 (s, 9H), 0.21 (s, 3H), 0.15 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 135.2, 134.0, 
132.6, 128.6, 121.8, 117.3, 90.9, 84.4, 70.9, 42.7, 39.5, 25.8, 22.8, 22.7, 18.2, -4.2, -5.2; 





6-tert-Butyldimethylsiloxyundec-1-en-7-yne (1.13a).  A solution of 1-hexen-6-al in 
CH2Cl2 (200 mL) and Et2O (200 mL) was prepared by PCC oxidation of 1-hexen-6-ol 
(3.6 mL, 30 mmol).99  To a 0 °C solution of 1-pentyne in Et2O (50 mL) was added n-
BuLi (16 mL, 2.71 M, 43 mmol) dropwise. The resulting acetylide solution was added by 
cannula to the solution of 1-hexen-6-al at -78 °C.  After 2 h the cooling bath was 
removed and the reaction mixture was stirred for 10 h at rt.  A solution of NH4Cl (60 mL, 
sat’d) was added and the layers were separated.  The aqueous phase was extracted with 
Et2O, and the combined organics were washed with brine (50 mL), dried (MgSO4), 
filtered and concentrated.  The resulting residue (1.67 g, 10 mmol) was taken up in DMF 
(2 mL) and added to a slurry of imidazole (1.89 g, 28 mmol) and TBSCl (1.84 g, 11 
mmol) at rt.  After 6 h the reaction mixture was poured into a stirred solution of NaHCO3 
(30 mL, sat’d).  The mixture was extracted with hexanes and the combined extracts were 
washed with water, dried (MgSO4), filtered and concentrated in vacuo. The residue was 
purified by flash chromatography on SiO2 (elution gradient: hexanes to 1% 
EtOAc/hexanes) to give the title compound as a colorless liquid (2.8 g, 11 mmol, 35%): 
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Rf 0.26 (hexanes); IR (thin film) ν  3078, 1641, 1253, 1089 cm-1; 1H NMR (300 MHz, 
CDCl3) δ 5.83 (dddd, J = 6.7, 6.7, 10.3, 16.9 Hz, 1 H), 5.08-4.94 (m, 2H), 4.36 (ddd, J = 
2.1, 2.1, 6.4, 6.4 Hz, 1H), 2.19 (app dt, J = 2.1, 6.9 Hz, 2H), 2.09 (app q,  J = 6.9 Hz, 2H), 
1.72-1.61 (m, 2H), 1.60-1.47 (m, 4H), 0.99 (s, 9H), 0.14 (s, 3H), 0.13 (s, 3H); 13C NMR 
(75 MHz, CDCl3) δ 138.8, 114.4, 84.3, 82.0, 63.0, 38.4, 33.4, 25.8, 24.6, 22.1, 20.7, 18.3, 
13.5, -4.5, -5.0; HRMS m/z 281.2294 (calc’d for C17H33OSi [M+H]+, 281.3001). 
 





3E-Ethylidene-1,1-bis(methoxymethyl)-4-methylcyclopentane (1.1b). To a solution of 
Cp2ZrCl2 (98 mg, 0.34 mmol) in THF (3 mL) cooled to -78 °C, was added n-BuLi (0.26 
mL, 2.56 M, 0.68 mmol) and the dry ice bath was removed. The reaction mixture was 
allowed to warm until homogenous (~0 °C), at which point the mixture was cooled to -78 
°C.  A solution of enyne 1.1a (63 mg, 0.32 mmol) in THF (1.5 mL) was added via 
cannula, and the dry ice bath was replaced with an ice bath.  After 1h the ice bath was 
removed and the reaction mixture was allowed to warm to rt.  After 12 h, HCl (0.5 mL, 3 
M, 1.5 mmol) was added and the mixture was stirred for 10 min.  The layers were 
separated and the aqueous phase was extracted with hexanes.  The combined extracts 
were washed with NaHCO3 (sat’d) and brine, dried (MgSO4), filtered and concentrated.  
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Purification by flash chromatography on SiO2 (hexanes to 2.5% EtOAc/hexanes) 
provided the title compound as a colorless oil (53 mg, 0.27 mmol, 84%): Rf 0.23 (2.5% 
EtOAc/hexanes); IR (thin film) ν  3035, 1198, 1111 cm-1; 1H NMR (300 MHz, CDCl3) δ 
5.18-5.08 (m, 1H), 3.31 (s, 3H), 3.30 (s, 3H), 3.25 (d, J = 8.7 Hz, 1H), 3.20 (d, J = 8.7 
Hz, 1H), 3.19 (s, 2H), 2.53-2.38 (m, 1H), 2.12 (s, 2H), 1.82 (dd, J = 7.7, 12.8 Hz, 1H), 
1.57-1.51 (m, 3H), 1.04-0.94 (m, 1 H), 1.00 (d, J = 6.7 Hz, 3H); 13C NMR (75 MHz, 
CDCl3) δ 146.9, 114.0, 77.8, 75.4, 59.3, 45.5, 40.6, 36.4, 35.7, 31.6, 18.6, 14.4; HRMS 







The title compound was prepared from enyne 1.2a (247 mg, 0.97 mmol) according to the 
procedure described for 1.1b  except that H2SO4 (1.3 mL, 10%) was used for protonation 
of the zirconocycle (colorless liquid, 236 mg, 0.92 mmol, 95%): Rf 0.33 (5% 
EtOAc/hexanes); IR (thin film) ν  1637, 1248, 1110, cm-1; 1H NMR (300 MHz, CDCl3) δ 
5.21 (ddd, J = 2.3, 2.3, 2.3 Hz, 1H), 3.31 (s, 3H), 3.31 (s, 3H), 3.22 (d, J = 11.0 Hz, 2H), 
3.19 (d, J = 11.0 Hz, 2H), 2.54-2.40 (m, 1H), 2.24 (app s, 2H), 1.84 (dd, J = 8.5, 13.1 Hz, 
1H), 1.02 (d, J = 6.7 Hz, 3H), 1.01 (dd, J = 10.8, 12.8 Hz, 1 H), 0.06 (s, 9H); 13C NMR 
(75 MHz, CDCl3) δ 165.8, 117.3, 77.4, 75.6, 59.3, 59.2, 45.6, 39.6, 39.2, 39.0, 18.7, -0.2; 






3E-Benzylidene-1,1-bis(methoxymethyl)-4-methylcyclopentane (1.4b).  The title 
compound was prepared from enyne 1.4a (129 mg, 0.50 mmol) according to the 
procedure described for 1.1b (light yellow oil, 116 mg, 0.45 mmol, 89%): Rf 0.35 (2.5% 
EtOAc/hexanes); IR (thin film) ν  3022, 1198, 1107, 747, 696 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.34-7.30 (m, 4H), 7.21-7.14 (m, 1H), 6.22 (ddd, J =  2.4, 2.4, 2.4 Hz, 1H), 3.34 
(s, 6H), 3.31 (d, J = 8.6 Hz, 1H), 3.28 (d, J = 8.6 Hz, 1H), 3.27 (s, 2H), 2.84-2.71 (m 1H), 
2.58 (d, J = 17.4 Hz, 1H), 2.52 (dd, J = 2.4, 17.4 Hz, 1H), 1.93 (dd, J = 7.9, 12.7 Hz, 1H) 
1.21 (d, J = 6.5 Hz, 3H), 1.14 (dd, J =11.3, 12.7 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 
149.7, 138.4, 128.2, 128.1, 125.7, 120.7, 77.5, 75.4, 59.2, 59.2, 46.5, 39.5, 38.4, 37.8, 
18.9; HRMS m/z 260.1768 (calc’d for C17H24O2 [M]+, 260.1776). 
BnO
1.5b  
trans-1-Benzyloxy-3E-ethylidene-2-methylcyclopentane (1.5b). The title compound 
was prepared from enyne 1.5a (107 mg, 0.50 mmol) according to the procedure described 
for 1.1b (colorless liquid, 89 mg, 0.41 mmol, 82%): Rf 0.44 (5% EtOAc/hexanes); IR 
(thin film) ν  3064, 3031, 1105, 736, 697 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.40-7.25 
(m, 5H), 5.31-5.23 (m, 1H), 4.63 (d, J = 2..0 Hz, 1H), 4.53 (d, J = 12.0 Hz, 1H) 3.45 (q, J 
= 6.6 Hz, 1H), 2.56-2.36 (m, 2H), 2.28-2.13 (m, 1H), 2.09-1.99 (m, 1H), 1.73-1.60 (m, 
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1H), 1.60 (d, J = 6.8 Hz, 3H), 1.10 (d, J = 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 
144.6, 138.9, 128.3, 127.4, 115.0, 86.1, 71.1, 44.6, 29.1, 25.5, 17.1, 14.0; HRMS m/z 





trimethylsilylvinylidenecyclopentane (1.8b). The title compound was prepared from 
enyne 1.8a (162 mg, 0.50 mmol) according to the procedure described for 1.1b (colorless 
liquid, 141 mg, 0.45 mmol, 91%): Rf 0.87 (hexanes); IR (thin film) ν  1636, 1249, 1079 
cm-1; 1H NMR (400 MHz, CDCl3) δ 5.18 (d, J = 2.4 Hz, 1H), 3.90 (s, 1H), 2.86-2.75 (m, 
1H), 1.99 (dd, J = 11.8, 11.8 Hz, 1H), 1.02 (s, 3H), 1.00 (s, 3H), 0.85 (s, 9H), 0.72 (s, 
3H), 0.11 (s, 9H), 0.06 (s, 3H), 0.02 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 167.5, 118.7, 
82.6, 44.7, 40.5, 35.8, 28.0, 25.8, 23.8, 19.1, 18.4, 0.6, -3.8, -4.3; HRMS m/z 327.2532 





The title compound was prepared from enyne 1.9b (164 mg, 0.50 mmol) according to the 
procedure described for 1.1b (colorless liquid, 122 mg, 0.39 mmol, 74%): Rf 0.74 
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(hexanes); IR (thin film) ν  3024, 1252, 1068, 737, 698 cm-1; 1H NMR (400 MHz, CDCl3) 
δ 7.35-7.19 (m, 5H), 6.30 (d, J = 3.60 Hz, 1H), 4.48 (s, 1H), 3.02-2.91 (m, 1H), 2.15 (dd, 
J = 12.0, 12.0 Hz, 1H), 1.20 (d, J = 8.8 Hz, 3H), 1.10 (dd, J = 8.0, 16.0 Hz, 1H), 1.07 (s, 
3H), 0.98 (s, 3H), 0.80 (s, 9H), -0.30 (s, 3H), -0.32 (s, 3H); 13C NMR (100 MHz, CDCl3) 
δ 154.1, 138.8, 128.5, 128.1, 126.2, 121.9, 79.1, 45.4, 41.6, 34.5, 28.1, 25.8, 23.7, 20.0, 






trimethylcyclopentane (1.10b). The title compound was prepared from enyne 1.10a 
(360 mg, 0.99 mmol) according to the procedure described for 1.1b (colorless liquid, 221 
mg, 0.64 mmol, 65%): Rf 0.70 (hexanes); IR (thin film) ν 1254, 1073, 836 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 7.29-7.24 (m, 2H), 7.18-7.13 (m, 2H), 6.19 (d, J = 2.7 Hz, 1H), 4.36 
(s, 1H), 2.98-2.87 (m, 1H), 2.10 (dd, J = 12.0, 12.0 Hz, 1H), 1.15 (d, J = 7.2 Hz, 3H), 
1.06 (dd, J = 5.1, 12.7 Hz, 1H), 1.03 (s, 3H), 0.92 (s, 3H), 0.77 (s, 9H), -0.30 (s, 3H), 
-0.35 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 155.0, 137.2, 131.9, 129.7, 128.3, 120.7, 
79.1, 45.2, 41.6, 34.6,  28.0, 35.7, 23.6, 19.9, 18.2, -4.8, -5.2; HRMS m/z 364.1980 




trans-1-tert-Butyldimethylsiloxy-2Z-butylidene-3-methylcyclohexane (1.13b). The 
title compound was prepared from enyne 1.13a (140 mg, 0.50 mmol) according to the 
procedure described for 1.1b (colorless liquid, 79 mg, 0.30 mmol, 59%): Rf 0.83 
(hexanes); IR (thin film) ν 1254, 1110 cm-1; 1H NMR (400 MHz, CDCl3) δ 4.95 (ddd, J = 
1.7, 7.2, 7.2 Hz, 1H), 4.75 (dd, J = 2.9, 2.9 Hz, 1H), 2.57-2.45 (m, 1H), 2.03 (app dq, J = 
3.8, 4.8, 13.3 Hz), 1.84-1.70 (m, 2H), 1.53-1.19 (m, 5H), 0.95-0.87 (m, 6H), 0.88 (s, 9H), 
0.04 (s, 3H), -0.03 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 145.4, 118.8, 66.1, 37.6, 35.8, 
32.1, 29.1, 25.8, 23.4, 20.4, 18.3, 18.0, 13.9, -4.7, -4.9; HRMS m/z 283.2449 (calc’d for 




1-tert-Butyldimethylsiloxy-2Z-ethylidene-3,5,5-trimethylcyclopentane (1.15b). The 
title compound was prepared from enyne 1.15a (133 mg, 0.50 mmol) according to the 
procedure described for 1.1b as an inseparable mixture of cis/trans isomers (1:1.5 dr) 
(colorless liquid, 111 mg, 0.44 mmol, 88%): 
trans: Rf 0.87 (hexanes); 1H NMR (400 MHz, CDCl3) δ 5.19 (dq, J = 2.39, 6.84 Hz, 1H), 
4.05 (s, 1H), 2.76-2.64 (m, 1H), 1.97 (dd, J = 10.94, 12.31 Hz, 1H), 1.71 (dd, J = 2.74, 
6.84 Hz, 3H), 1.03 (d, J = 6.84 Hz, 3H), 1.00 (s, 3H), 0.95 (dd, J = 5.47, 12.31 Hz, 1H), 
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0.87 (s, 9H), 0.77 (s, 3H), 0.07 (s, 3H), 0.02 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 
150.6, 115.5, 79.5, 45.5, 41.2, 34.0, 27.8, 25.9, 23.6, 19.6, 18.3, 15.0, -4.4, -4.5; HRMS 
m/z 269.2293 (calc’d for C16H33OSi [M+H]+, 269.2301) 
 
cis:  Rf 0.87 (hexanes); 1H NMR (400 MHz, CDCl3) δ 5.29 (ddq, J = 0.7, 1.7, 6.8 Hz, 
1H), 3.94 (s, 1H), 2.52-2.39 (m, 1H), 1.70 (dd, J = 1.7, 6.8 Hz, 3H), 1.52 (dd, J = 8.2, 
12.0 Hz, 1H), 1.40 (dd, J = 8.6, 12.3 Hz, 1H), 1.10 (d, J = 7.2 Hz, 3H), 1.01 (s, 3H), 0.88 
(s, 9H), 0.73 (s, 3H), 0.08 (s, 3H), 0.03 (s, 3H);  13C NMR (100 MHz, CDCl3) δ 150.6, 
118.8, 78.7, 44.9, 43.0, 36.1, 25.9, 25.4, 23.8, 23.4, 18.3, 15.5, -4.2, -4.6. 






3E-Ethylidene-4-hydroxymethyl-1,1-bis(methoxymethyl)cyclopentane (1.1c).  To a 
solution of Cp2ZrCl2 (306 mg, 1.05 mmol) in THF (3 mL) cooled to -78 °C, was added 
n-BuLi (0.81 mL, 2.71 M, 2.20 mmol) and the dry ice bath was removed. The reaction 
mixture was allowed to warm until homogenous (~0 °C), at which point the mixture was 
cooled to - 78 °C.  A solution of enyne 1.1a (0.190 mg, 0.97 mmol) in THF (1.5 mL) was 
added via cannula, and the dry ice bath was replaced with an ice bath.  After 1h the ice 
bath was removed and the reaction mixture was allowed to warm to rt.  Neat (cHex)2BCl 
(0.50 mL, 2.3 mmol) was added 12 h later by syringe.  After 5 h the borane was oxidized 
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by successive treatment with aqueous NaOH (2 mL, 7.5M, 15 mmol) and H2O2 (2 mL, 
30%) using a water bath to control the exotherm.  The reaction mixture was then heated 
at 50 °C for 1h, allowed to cool, and the layers were separated.  The aqueous layer was 
extracted with EtOAc and the extracts were washed with Na2SO3 (10%), NaHCO3 (sat’d) 
and brine, dried (MgSO4), filtered and concentrated.  Purification of the residue by flash 
chromatography on SiO2 (elution gradient: hexanes to 30% EtOAc/hexanes) provided the 
title compound as a colorless oil (156 mg, 0.73 mmol, 75%): Rf 0.18 (30% 
EtOAc/hexanes); IR (thin film) ν  3386 (br), 1198, 1109 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 5.30 (dddq, J = 2.1, 2.4, 2.4, 6.8 Hz, 1H), 3.58 (d, J = 5.5 Hz, 2H), 3.32 (s, 3H), 
3.30 (s, 3H), 3.30 (d, J = 8.9 Hz, 1H), 3.26 (d, J = 8.9 Hz, 1H), 3.17 (d, J = 11.1 Hz, 1H), 
3.15 (d, J = 11.1 Hz, 1H), 2.72-2.61 (m, 1H), 2.23 (d, J = 16.7 Hz, 1H), 2.07 (dd, J = 2.1, 
16.7 Hz, 1H), 1.81 (dd, J = 7.5, 13.0 Hz, 1H), 1.58 (d, J = 6.8 Hz, 3H), 1.36 (dd, J = 9.2, 
13.0 Hz, 1H) 13C NMR (100 MHz, CDCl3) δ 142.4, 116.8, 77.4, 75.3, 65.4, 59.3, 46.1, 








(1.2c). The title compound was prepared from enyne 1.2a (250 mg, 0.98 mmol) according 
to the procedure described for 1.1c except a solution of NaOOH prepared from NaOH (2 
mL, 6 M, 12 mmol) and H2O2 (4 mL, 30%, 35 mmol) was used for oxidation (colorless 
liquid, 171 mg, 0.63 mmol, 64%): Rf 0.30 (25% EtOAc/hexanes); IR (thin film) ν 3447 
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(br), 1653, 1107 cm-1; 1H NMR (300 MHz, CDCl3) δ 5.40 (ddd, J = 1.8, 2.1, 2.1 Hz, 1H), 
3.68-3.58 (m, 2H), 3.35 (s, 3H), 3.33 (s, 3H), 3.30 (s, 2H), 3.20 (d, J = 12.6 Hz, 1H), 3.17 
(d, J = 12.6 Hz, 1H), 2.74-2.62 (m, 1H), 2.35 (d, J = 16.4 Hz, 1H), 2.21 (dd, J =2.05, 16.4 
Hz, 1H), 1.82 (dd, J = 8.7, 13.3 Hz, 1H, 1.74 (br s, 1H), 1.43 (dd, J = 8.7, 13.3 Hz, 1H), 
0.10 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 161.2, 121.0, 77.1, 75.2, 65.4, 59.2, 59.2, 




























3E-Benzylidene-4-hydroxymethyl-1,1-bis(methoxymethyl)cyclopentane (1.4c).  The 
title compound was prepared from enyne 1.4a (256 mg, 0.99 mmol) according to the 
procedure described for 1.1c (colorless oil, 227 mg, 0.82 mmol, 83%): Rf 0.20 (25% 
EtOAc/hexanes); IR (thin film) ν  3417 (br),1108 cm-1; 1H NMR (400 MHz, CDCl3) δ 
7.35-7.25 (m, 4H), 7.22-7.15 (m, 1H), 6.37 (s, 1H), 5.73 (d, J = 5.8 Hz, 2H), 3.39-3.31 
(m, 2H), 3.36 (s, 3H), 3.28 (s, 3H), 3.17 (s, 2H), 2.98-2.87 (m, 1H), 2.60 (d, J = 17.1 Hz, 
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1H), 2.50 (d, J = 17.1 Hz, 1H), 1.99 (br s, 1H), 1.90 (dd, J = 8.6, 13.0 Hz, 1H), 1.47 (dd, J 
= 8.9, 13.0 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 145.2, 137.9, 128.4, 128.1, 126.1, 
123.0, 77.1, 75.3, 65.9, 59.2, 59.2, 47.3, 46.6, 37.9, 33.3; HRMS m/z 277.1812 (calc’d for 





trans-1-Benzyloxy-3E-ethylidene-2-hydroxymethylcyclopentane (1.5c). The title 
compound was prepared from enyne 1.5a (211 mg, 0.99 mmol) according to the 
procedure described for 1.1c except transmetallation time was extended to 28 h (colorless 
oil, 147 mg, 0.63 mmol, 64%): Rf 0.37 (25% EtOAc/hexanes); IR (thin film) ν  3418 (br), 
3031, 1095, 735, 697 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.36-7.25 (m, 5H), 5.31 (dddq, 
J = 2.1, 2.3, 2.6, 6.7 Hz, 1H), 4.61 (d, J = 11.8 Hz, 1H), 4.52 (d, J = 11.8 Hz, 1H), 3.87 
(ddd, J = 6.2, 6.2, 6.2 Hz, 1H), 3.70 (dd, J = 4.9, 10.8 Hz, 1H), 2.70-2.59 (m, 1H), 2.51-
2.36 (m, 1H), 2.25-2.10 (m, 1H), 2.09-1.92 (m, 1H), 1.78-1.65 (m, 1H), 1.65-1.57 (m, 
3H); 13C NMR (75 MHz, CDCl3) δ 139.8, 138.4, 128.4, 127.6, 127.6, 117.2, 82.9, 71.1, 









trimethylsilylvinylidenecyclopentane (1.8c). The title compound was prepared from 
enyne 1.8a (315 mg, 0.97 mmol) according to the procedure described for 1.1c except a 
solution of NaOOH prepared from NaOH (2 mL, 6 M, 12 mmol) and H2O2 (4 mL, 30%, 
35 mmol) was used for oxidation (white solid, 170 mg, 0.52 mmol, 54%): Rf 0.36 (10% 
EtOAc/hexanes); IR (thin film) ν  3318 (br), 1635, 1249, 1078 cm-1; 1H NMR (400MHz, 
CDCl3) δ 5.26 (d, J = 2.4 Hz, 1H), 3.90 (s, 1H), 3.79 (dd, J = 5.1, 10.9 Hz, 1H), 3.61 (dd, 
J = 6.5, 10.9 Hz, 1H), 3.02-2.91 (m, 1H), 1.92 (dd, J = 12.1, 12.1 Hz, 1H), 1.41 (br s, 
1H), 1.24 (dd, J = 4.8, 12.7 Hz, 1H), 1.02 (s, 3H), 0.85 (s, 9H), 0.74 (s, 3H), 0.12 (s, 9H), 
0.06 (s, 3H), 0.02 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 162.8, 120.1, 82.9, 65.0, 43.8, 
40.5, 39.3, 27.4, 25.8, 23.7, 18.4, 0.6, -3.8, -4.3; HRMS m/z 343.2459 (calc’d for 







trimethylsilylvinylidenecyclopentane (1.8g).  
The title compound accompanied 1.8c in the cyclization/oxidation reaction of enyne 1.8a 
(white solid, 69 mg, 0.30 mmol, 31%): Rf 0.27 (30% EtOAc/hexanes); IR (thin film) ν  
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3276 (br), 1629, 1245, 1138 cm-1; 1H NMR (400MHz, CDCl3) δ 5.59 (dd, J = 2.2, 2.2 Hz, 
1H), 3.86 (br s, 1H), 3.61 (dd, J = 4.8, 18.5 Hz, 1H), 3.58 (dd, J = 6.8, 18.5 Hz, 1H), 
2.84-2.74 (m, 1H), 1.71 (dd, J = 8.9, 13.0 Hz, 1H), 1.39 (dd, J = 8.6, 13.0 Hz, 1H), 1.65-
1.44 (br s, 2H), 1.10 (s, 3H), 0.68 (s, 3H), 0.13 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 
162.4, 120.0, 82.9, 67.1, 40.5, 40.0, 38.9, 26.4, 19.6, 0.1; HRMS m/z 227.1472 (calc’d for 




 trans-2-trimethylsilylmethyl-3-hydroxymethyl-5,5-dimethylcyclopentanone (1.8h).  
A solution of diol 1.8g (12 mg, 0.053 mmol) in CDCl3 (0.75 mL) was allowed to stand at 
rt for 3 d.  Concentration and flash chromatography of the residue on SiO2 (elution 
gradient: 5% EtOAc/hexanes to 30 % EtOAc/hexanes) provided the title compound as a 
white solid (11 mg, 0.48 mmol, 91%): Rf 0.41 (30% EtOAc/hexanes); IR (thin film) ν  
3458 (br), 1737, 1248 cm-1; 1H NMR (400MHz, CDCl3) δ 3.84 (dd, J = 3.3, 10.8 Hz, 1H), 
3.64 (dd, J = 5.6, 10.8 Hz, 1H), 2.11-1.8 (m, 3H), 1.52 (ddd, J = 2.6, 12.8, 12.8 Hz, 1H), 
1.60-1.45 (br s, 1H), 1.08 (s, 3H), 1.00 (s, 3H), 0.81 (dd, J= 7.9, 14.9 Hz, 1H), 0.69 (dd, J 
= 4.4, 14.9 Hz, 1H) 0.02 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 224.0, 64.7, 47.2, 44.7, 
43.9, 40.1, 25.4, 25.0, 16.5, -0.7; HRMS m/z 228.1548 (calc’d for C12H24O2Si [M]+, 







trimethylsilylvinylidinecyclopentane (1.8f). To a solution of TBS ether 1.8c (0.072 g, 
0.21 mmol) in MeOH (4 mL) was added HF•pyridine (1.2 mL, 20%, 2.4 mmol) at rt. The 
reaction mixture was heated to 60 °C and after 24 h was allowed to cool to rt. Aqueous 
NaHCO3 (15 mL, sat’d) was added and the resulting mixture was extracted with EtOAc. 
The combined extracts were washed with brine, dried (MgSO4), filtered and 
concentrated. Purification of the residue by flash chromatography on SiO2 (elution 
gradient: 5% EtOAc/hexanes to 30% EtOAc/hexanes) provided the title compound as a 
white solid (16 mg, 0.070 mmol, 33%). The starting silyl ether was also recovered (14 
mg, 0.041 mmol, 19%): Rf 0.44 (30% EtOAc/hexanes); IR (thin film) ν 3385 (br), 1626, 
1246, 1088 cm-1; 1H NMR (400 MHz, CDCl3) δ 5.55 (dd, J = 2.4, 2.4 Hz, 1H), 4.00 (app 
d, J = 7.9 Hz, 1H), 3.62 (app d, J = 5.3 Hz, 1H), 2.75-2.65 (m, 1H), 1.88 (dd, J = 8.9, 13.0 
Hz, 1H), 1.38 (br s, 1H), 1.35 (dd, J = 9.6, 13.0 Hz, 1H), 1.03 (s, 3H), 0.85 (s, 3H), 0.12 
(s, 9H); 13C NMR (100 MHz, CDCl3) δ 124.6, 83.1, 66.0, 44.2, 40.5, 39.2, 26.7, 20.4, 









The title compound accompanied 1.8f in the deprotection of TBS ether 1.8c (15 mg, 
0.096 mmol, 46%): Rf 0.16 (30% EtOAc/hexanes); IR (thin film) ν 3349, 1662, 1092, 
1029 cm-1; 1H NMR (400 MHz, CDCl3) δ 5.18 (dd, J = 2.7, 2.7 Hz, 1H), 5.07 (dd, J = 
2.7, 2.7 Hz, 1H), 3.94 (br s, 1H), 3.62 (dd, J = 6.2, 10.6 Hz, 1H), 3.53 (dd, J = 5.8, 10.9 
Hz, 1H), 2.75-2.64 (m, 1H), 1.67 (dd, J = 8.5, 13.0 Hz, 1H), 1.52 (br s, 1H), 1.40 (br s, 
1H), 1.27 (dd, J = 9.6, 13.0 Hz, 1H), 1.08 (s, 3H), 0.76 (s, 3H); 13C NMR (100 MHz, 
CDCl3) δ 154.7, 107.8, 82.2, 66.2, 41.2, 40.5, 38.6, 26.2, 19.5; HRMS m/z 155.1072 






dimethylcyclopentane (1.9c). The title compound was prepared from enyne 1.9a (322 
mg, 0.98 mmol) according to the procedure described for 1.1c (colorless oil, 239 mg, 
0.72 mmol, 74%): Rf 0.30 (15% EtOAc/hexanes); IR (thin film) ν  3436, 1255, 1067, 
734, 650 cm-1; 1H NMR (400MHz, CDCl3) δ 7.34-7.28 (m, 2H), 7.26-7.18 (m, 3H), 6.43 
(d, J = 2.4 Hz, 1H), 4.49 (s, 1H), 3.91 (dd, J = 5.1, 10.60 Hz, 1H), 3.72 (dd, J = 10.6, 7.2 
Hz, 1H), 3.11 (m, 1H), 2.07 (dd, J = 12.0, 12.0 Hz, 1H), 1.90 (br s, 1H), 1.43 (dd, J = 4.1, 
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12.7 Hz, 1H), 1.09 (s, 3H), 0.99 (s, 3H), 0.79 (s, 9H), -0.33 (s, 3H), -0.35 (s, 3H) 13C 
NMR (100 MHz, CDCl3) δ 149.5, 138.1, 128.5, 128.1, 126.5, 122.8, 79.3, 65.8, 42.5, 
41.6, 40.0, 27.4, 25.7, 23.5, 18.1, -5.0, -5.5; HRMS m/z 347.2398 (calc’d for C21H35O2Si 







5,5-dimethylcyclopentane (1.10c). The title compound was prepared from enyne 1.10a 
(360 mg, 0.99 mmol) according to the procedure described for 1.1c (colorless oil, 227 
mg, 0.62 mmol, 63%): Rf 0.57 (25% EtOAc/hexanes); IR (thin film) ν  3329 (br), 1383, 
1361, 1254, 1071 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.26 (d, J = 8.5 Hz, 2H), 7.13 (d, J 
= 8.5 Hz, 2H), 6.36 (d, J = 2.3 Hz, 1H), 4.38, (s, 1H), 3.87 (dd, J = 5.4, 10.5 Hz, 1H), 
3.70 (dd, J = 6.9, 10.5 Hz, 1H), 3.14-3.02 (m, 1H), 2.04 (dd, J = 12.0, 12.0 Hz, 1H), 1.53 
(br s, 1H), 1.37 (dd, J = 4.6, 13.1 Hz, 1H), 1.05 (s, 3H), 0.94 (s, 3H), 0.76 (s, 9H), -0.31 
(s, 3H), -0.38 (s, 3H); 13C NMR(75 MHz, CDCl3) δ 150.4, 136.6, 132.2, 129.8, 128.3, 
121.5, 79.3, 65.8, 42.6, 41.6, 39.9, 27.4, 25.7, 23.4, 18.1, -4.9, -5.2; HRMS m/z 380.1948 








(1.13c). The title compound was prepared from enyne 1.13a (276 mg, 0.99 mmol) 
according to the procedure described for 1.1c (colorless oil, 147 mg, 0.62 mmol, 62%): Rf 
0.32 (10% EtOAc/hexanes); IR (thin film) ν 3316 (br), 1252, 1037 cm-1; 1H NMR (400 
MHz, CDCl3) δ 4.92 (dddd, J = 1.0, 7.2, 7.2, 7.2 Hz, 1H), 4.73 (ddd, 2.7, 2.7, 2.7 Hz, 
1H), 3.77 (dd, J = 6.5, 10.6 Hz, 1H), 3.54 (dd, J = 6.2, 10.6 Hz, 1 H), 2.66-2.56 (m, 1H), 
2.03 (app dq, J = 1.0, 7.4 Hz, 2H), 1.96-1.75 (m, 3H), 1.53-1.45 (m, 1H), 1.43-1.22, (m, 
4H), 1.01-0.92 (m, 1H) 0.88 (dd, J = 3.4, 3.4 Hz, 3H), 0.86 (s, 9H), 0.02 (s, 3H), -0.03 (s, 
3H); 13C NMR (100 MHz, CDCl3) δ 142.1, 119.3, 65.9, 64.9, 40.1, 35.9, 31.9, 29.1, 25.8, 







dimethylcyclopentane (1.15c).  The title compound was prepared from enyne 1.15a (262 
mg, 0.98 mmol) according to the procedure described for 1.1c as a mixture of cis/trans 
isomers (1:1.5 dr) (colorless oil, 213 mg, 0.79 mmol, 81%):  
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trans: Rf 0.63 (25% EtOAc/hexanes); IR (thin film) ν  3332 (br),1382, 1361, 1251, 1079 
cm-1; 1H NMR (300 MHz, CDCl3) δ 5.29 (q, J = 6.9 Hz, 1H), 4.05 (s, 1H), 3.72 (dd, J = 
5.1, 10.5 Hz, 1H), 3.55 (dd, J = 6.7, 10.5 Hz, 1H), 2.89-2.75 (m, 1H), 1.87 (dd, J = 11.0, 
12.8 Hz, 1H), 1.70 (dd, J = 2.6, 6.9 Hz, 3H), 1.44 (br s, 1H), 1.24 (dd, J = 5.4, 12.8 Hz), 
0.98 (s, 3H), 0.85 (s, 9H), 0.77 (s, 3H), 0.05 (s, 3H), 0.00 (s, 3H); 13C NMR(75 MHz, 
CDCl3) δ 145.8, 117.0, 79.9, 65.7, 42.2, 41.2, 39.8, 27.2, 25.8, 23.3, 18.2, 14.9, -4.36, 


























cis: Rf 0.73 (25% EtOAc/hexanes); IR (thin film) ν 3354 (br),1382, 1360, 1251, 1072 
cm-1; 1H NMR (300 MHz, CDCl3) δ 5.44 (q, J = 6.9 Hz, 1H), 3.96 (s, 1H) 3.60 (dd, J = 
4.4, 9.7 Hz, 1H), 3.54-3.46 (m, 1H), 2.72-2.61 (m, 1H), 2.39 (br s, 1H), 1.73-1.63 (m, 
4H), 1.45 (dd, J = 9.0, 12.8 Hz, 1H), 1.01 (s, 3H), 0.86 (s, 9H), 0.76 (s, 3H), 0.10 (s, 3H), 
0.04 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 146.0, 121.6, 78.3, 66.7, 44.3, 42.9, 38.0, 

































Ethylmorpholine glyoxylate (2.24). Ethyl oxalyl chloride (11.4 mL, 100 mmol, 1 eq) 
was added dropwise to a solution of morpholine (9.2 mL, 105 mmol, 1.05 eq) and Et3N 
(14.5 mL, 105 mmol, 1.05 eq) in CH2Cl2 (200 mL) at 0 °C. The reaction mixture was 
allowed to warm to rt and after 16 h was washed with HCl (1 N), NaHCO3 (sat’d) and 
brine. The organic layer was dried (MgSO4), filtered and concentrated, providing the title 







Morpholine 5,5-dimethyl-2,4-dioxohexanamide (2.25). A solution of t-BuOK (23 g, 
205 mmol 2.1 eq) in THF (180 mL) was added via cannula to a solution of pinacolone 
(12 mL, 96 mmol, 1.0 eq) and amide 2.24 (18 g, 96 mmol, 1.0 eq) in THF (40 mL) over 
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40 min at rt. After 3 h, AcOH (20 mL, 350 mmol, 3.6 eq) was added over 5 min and the 
resulting heterogeneous mixture was filtered and the solids were washed with CH2Cl2. 
The filtrate was washed with NaHCO3 and brine, dried, filtered and concentrated. 
Purification of the resulting oil by flash chromatography (SiO2, 50% EtOAc/hexanes) 











Co(modp)2 (CoII(modp)2 (2.26). Cobalt(II) 2-ethylhexanoate (19.8 mL, 1.88 M in 
mineral spirits, 37 mmol, 1.0 eq) was added at rt over 10 min to a solution of ligand 
Error! Reference source not found. (18 g, 75 mmol, 2.0 eq) in benzene (200 mL). After 
16 h hexanes was added until no additional solids precipitated and the reaction mixture 
was centrifuged. The supernatant layer was decanted and the solids were washed with 
hexanes and centrifuged an additional four times.  Removal of the residual solvent under 
reduced pressure provided Co(modp)2 as a tan solid (18.9 g, 95%). 
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6-Methyl-1-phenylhept-6-en-3-ol (2.28a), The title compound was prepared from 2-
methyl-4-bromobut-1-ene (4.6 g, 31 mmol) according to the procedure described for 2.29 
except the crude product was purified by vacuum distillation (96-98 °C, 0.8 mm Hg) to 
give a colorless oil (1.74 g, 8.0 mmol, 61%): Rf 0.53 (30% EtOAc/hexanes); 1H NMR 
(400 MHz, CDCl3) δ 7.30-7.24 (m, 2H), 7.21-7.14 (m, 3H), 4.71 (app s, 1H), 4.70 (app s, 
1H), 3.64 (dddd, J = 4.4, 4.4, 7.9, 7.9, 1H), 2.84-2.73 (m, 1H), 2.71-2.61 (m, 1H), 2.21-
2.01 (m, 2H), 1.81-1.75 (m, 2H), 1.72 (s, 3H), 1.66-1.56 (m, 2H), 1.55 (br s, 1H); 13C 
NMR (100 MHz, CDCl3) δ 145.7, 142.1, 128.3, 125.7, 110.1, 71.1, 39.0, 35.2, 33.9, 32.0, 





E-1-Phenylnon-6-en-3-ol (2.29a). To a suspension of Mg (2.3 g, 96 mmol) in Et2O (30 
mL) was added 1,2-dibromoethane (0.50 mL, 5.8 mmol) and the resulting mixture was 
heated to reflux. After 30 min, a solution of E-1-bromohex-3-ene (6.5 g, 40 mmol) in 
Et2O (10 mL) was added dropwise. After 30 min, hydrocinnamaldehyde (4.4 mL, 33 
mmol) was added dropwise. After addition, the reaction mixture was allowed to cool to rt 
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and aqueous NH4Cl (20 mL, sat’d) was added carefully. The reaction mixture was 
filtered and the filtrate was washed with NaHCO3 (sat’d) and brine, dried (Na2SO4), 
filtered and concentrated. The residue was purified by flash chromatography on SiO2 
(elution gradient: 10% EtOAc/hexanes to 30% EtOAc/hexanes), providing the title 
compound as a white solid (3.24 g, 15 mmol, 54%): Rf 0.46 (30% EtOAc/hexanes); 1H 
NMR (400 MHz, CDCl3) δ 7.35-7.29 (m 2H), 5.54 (ddd, J = 6.2, 6.2, 15.4 Hz, 1H), 5.45 
(J = 1.4, 1.4, 6.2, 6.2, 15.4 Hz, 1H), 2.84 (ddd, J = 5.8, 9.6, 13.7 Hz, 1H), 2.71 (6.8, 9.2, 
13.7 Hz, 1H), 2.24-2.00 (m, 5H), 1.88-1.73 (m, 2H), 1.66-1.51 (m, 2H), 1.02 (dd, J = 7.5, 
7.5 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 142.5, 132.9, 129.0, 128.71, 128.67, 126.1, 






Z-1-Phenylnon-6-en-3-ol (2.30a). The title compound was prepared from Z-1-
bromohex-3-ene (5.4 g, 33 mmol) according to the procedure described for 2.29 (white 
solid, 3.6 g, 16 mmol, 50%): Rf 0.50 (30% EtOAc/hexanes); 1H NMR (400 MHz, CDCl3) 
δ 7.31-7.25 (m, 2H), 7.22-7.15 (m, 3H), 5.40 (ddd, J = 6.8, 6.8, 10.9 Hz, 1H), 5.33 (ddd, J 
= 7.2, 7.2, 10.9 Hz, 1H), 2.79 (ddd, J = 6.2, 9.9, 13.7 Hz, 1H), 2.66 (ddd, J = 6.8, 9.6, 
13.7 Hz, 1H), 2.23-1.99 (m, 4H), 1.84-1.68 (m, 2H), 1.59 (br s, 1H), 1.58-1.46 (m, 2H), 





128.36, 125.8, 71.1, 39.1, 37.4, 32.0, 23.4, 20.5, 14.3; HRMS m/z 219.1740 (calc’d for 





7-Methyl-1-phenyl-oct-6-en-3-ol ( 2.31a). The title compound was prepared from 2-
methyl-5-bromopent-2-ene (6.5 g, 40 mmol) according to the procedure described for 
2.29 (colorless oil, 1.7 g, 8.0 mmol, 42%): Rf 0.55 (30% EtOAc/hexanes); 1H NMR (300 
MHz, CDCl3) δ 7.31-7.24 (m, 2H), 7.22-7.13 (m, 3H), 5.12 (dd, J = 7.4, 7.4 Hz, 1H), 
3.63 (br s, 1H), 2.79 (ddd, J = 6.9, 9.7, 13.8 Hz, 1H), 2.65 (ddd, J = 6.9, 9.0, 13.6 Hz, 
1H), 2.08 (app dddd, J = 7.9, 7.9, 15.1, 15.1 Hz, 2H), 1.80-1.70 (m, 2H), 1.68 (s, 3H), 
1.61 (s, 3H), 1.56-1.45 (m, 3H); 13C NMR (75 MHz, CDCl3) δ 142.2, 132.2, 128.40, 
128.37, 125.8, 124.0, 71.2, 39.1, 37.4, 32.1, 25.7, 24.4, 17.7; HRMS m/z 219.1745 







(2.101). A solution of allylmagnesium bromide (50 mL, 1.0 M, 50 mmol) was added 






After 30 min, a solution of triflate 2.47 (13.1 g, 30 mmol) in Et2O (200 mL) was added 
dropwise. After 16 h, the reaction mixture was poured, cold, into a stirred aqueous 
solution of NH4Cl (200 mL, sat’d) and the resulting mixture was allowed to warm to rt. 
After 45 min, the layers were separated and the aqueous layer was extracted with Et2O. 
The combined extracts were washed with NaHCO3 (sat’d) and brine, dried (MgSO4), 
filtered and concentrated. Purification of the crude material by flash chromatography on 
SiO2 (elution gradient: 13% Et2O/hexanes to 35% Et2O/hexanes provided the title 
compound as a colorless oil (6.59 g, 20 mmol, 67%): Rf 0.48 (50% Et2O/hexanes); 1H 
NMR (300 MHz, CDCl3) δ 7.76 (d, J = 8.5 Hz, 2H), 7.32 (d, J = 8.5 Hz, 2H), 5.84-5.66 
(m, 1H), 5.65-5.66 (m 2H), 4.08 (dd, J = 4.1, 11.0 Hz, 1H), 4.03 (dd, J = 4.1, 10.8 Hz, 
1H), 3.84-3.72 (m, 2H), 2.42 (s, 3H), 2.24- 1.98) (m,  2H), 1.69-1.52 (m, 2H), 1.33 (s, 
3H), 1.27 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 145.0, 137.4, 132.6, 129.8, 127.9, 115.1, 





(2R,3R)-2,3-dihydroxy-1-(p-toluene-4-sulfonoxy)hept-6-ene (2.48). To a rt solution of 
tosylate (2.101 (6.59 g, 20 mmol) in THF (125 mL) was added aqueous HCl (125 mL, 
3.0 N, 375 mmol) in one portion and the resulting mixture was heated to 35 °C. After 16 
h, the reaction mixture was allowed to cool to rt and K2CO3 (65 g, 471 mmol) was 
carefully added in small portions. After gas evolution ceased, the layers were separated 
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and the aqueous layer was extracted with CH2Cl2. The combined organic layers were 
washed with brine, dried (MgSO4), filtered and concentrated. The residual oil was 
purified by flash chromatography on SiO2 (elution gradient: 25% EtOAc/hexanes to 50% 
EtOAc/hexanes) to provide the title compound as a colorless oil (5.82 g, 19 mmol, 97%): 
Rf 0.36 (50% EtOAc/hexanes); 1H NMR (300 MHz, CDCl3) δ 7.76 (d, J = 8.5 Hz, 2H), 
7.32 (d, J = 8.5 Hz, 2H), 5.75 (dddd, J = 6.7, 6.7, 10.2, 16.9 Hz, 1H)< 6.02-4.89 (m, 2H), 
4.07 (dd, J = 4.9, 10.5Hz, 1H), 4.02 (dd, J = 6.7, 10.5 Hz, 1H), 3.68 (ddd, J = 3.8, 3.8, 6.7 
Hz, 1H), 3.57 (ddd, J = 3.8, 3.8, 8.2 Hz, 1H), 2.68, (br s, 2H) 2.41 (s, 3H), 2.24-2.19 (m, 
2H), 1.66-1.42 (m, 2H); 13C NMR (75 MHz, CDCl3) δ 145.2, 137.8, 132.3, 129.9, 127.9, 





(1’R,1R)-1-Oxiranylpent-4-en-1-ol (2.102).A solution of diol tosylate 2.48 (7.9 g, 25 
mmol) in MeOH (65 mL) was added dropwise at rt to a suspension of anhydrous K2CO3 
(10.9 g, 79 mmol) in MeOH (25 mL). After 1 h, the reaction mixture was poured into a 
stirred aqueous solution of NH4Cl (100 mL, sat’d). The mixture was extracted with Et2O 
and the combined extracts were washed with NH4Cl (sat’d), NaHCO3 (sat’d) and brine, 
dried (MgSO4), filtered and concentrated. Purification of the crude material by vacuum 
distillation (50-52 °C, 0.2 mm Hg) provided the title compound as a colorless liquid (2.7 
g, 21 mmol, 84%): Rf 0.39 (50% EtOAc/hexanes); 1H NMR (400 MHz, CDCl3) δ 5.79 
(dddd, J = 6.7, 6.7, 10.0, 16.9 Hz, 1H), 5.01 (dddd, J = 1.5, 1.5, 1.5, 17.2 Hz, 1H), 4.99 
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(dd, J = 1.3, 10.2 Hz, 1H), 3.34 (ddd, 5.6, 5.6, 10.8 Hz, 1H), 2.95 (ddd, J = 2.8, 4.6, 7.2 
Hz, 1H), 2.78 (dd, J = 4.6, 4.6 Hz, 1H), 2.67 (dd, J = 2.6, 4.9, 1H), 2.32 (br s, 1H), 2.26-
2.06 (m, 2H), 1.76-1.66 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 137.8, 115.1, 71.0, 55.3, 




(1’R,1R)-1-oxiranyl-1-tert-butyldimethylsiloxypent-4-ene (2.49). A mixture of TBSCl 
(2.85 g, 19 mmol) and imidazole (2.92 g, 43 mmol) was dissolved in DMF (5 mL) at rt. 
A solution of epoxy alcohol 2.102 (2.21 g, 17.2 mmol) in DMF (4 mL) was added 
dropwise via cannula. After 5 h, the reaction mixture was diluted with water (50 mL) and 
extracted with Et2O. The combined extracts were washed with water and brine, dried 
(MgSO4), filtered and concentrated. Purification of the crude material by flash 
chromatography on SiO2 (elution gradient: hexanes to 5% EtOAc/hexanes provide the 
title compound as a colorless oil (3.82 g, 16 mmol, 92%): Rf 0.28 (5% EtOAc/hexanes); 
1H NMR (400 MHz, CDCl3) δ 5.80 (dddd, J = 6.5, 6.5, 9.9, 16.7 Hz, 1H), 5.02 (dddd, J = 
1.4, 1.4, 1.4, 17.1 Hz, 1H), 4.97 (dddd, J = 1.4, 1.4, 1.4, 10.6 Hz, 1H), 3.27 (ddd, J = 5.5, 
6.8, 7.5 Hz, 1H), 2.92 (ddd, J = 2.7, 4.1, 6.8 Hz, 1H), 2.78 (dd, J = 4.1 5.1 Hz, 1H), 2.34 
(dd, J = 2.7, 4.8 Hz, 1H), 2.25-2.03 (m, 2H), 1.71-1.34 (m, 2H), 0.91 (s, 9H), 0.12 (s, 
3H), 0.06 (s. 3H); 13C NMR (100 MHz, CDCl3) δ 138.2, 114.8, 74.0, 55.8, 44.8, 33.9, 








(4R,5R)-1-Phenylnon-8-ene-4,5-diol (2.46a). To a suspension of Mg (1.34 g, 56 mmol) 
in Et2O (15 mL) was added 1,2-dibromoethane (0.43 mL, 5.0 mmol) at rt and the reaction 
mixture was heated to reflux. After 30 min, a solution of 2-bromoethylbenzene (3.84 mL, 
28 mmol) in Et2O (25 mL) was added dropwise. After 20 min and allowing the reaction 
mixture to cool to rt, the solution was added dropwise via cannula to a suspension of 
CuBr•SMe2 (0.81 g, 3.9 mmol) at -30 °C, followed by dropwise addition of epoxide 2.49 
(3.17 g, 13 mmol). After 3 h, aqueous NH4Cl (20 mL, sat’d) was carefully added, 
followed by H2O (100 mL). The layers were separated and the aqueous layer was 
extracted with Et2O. The organic layers were washed with brine, dried (MgSO4), filtered 
and concentrated. The crude material was dissolved in THF (20 mL) and NBu4F (20 mL, 
1.0 M, 20 mmol) was added dropwise and the reaction mixture was allowed to warm to 
rt. After 12 h, H2O (50 mL) was added and the mixture was extracted with EtOAc. The 
combined extracts were washed with brine, dried (MgSO4), filtered and concentrated. 
Purification of the residue by flash chromatography on SiO2 (elution gradient: 30% 
EtOAc/hexanes to 50% EtOAc/hexanes) provided the title compound as a colorless oil 
(2.21 g, 9.5 mmol, 73%): Rf 0.37 (50% EtOAc/hexanes); 1H NMR (400 MHz, CDCl3) δ 
7.32-7.25 (m, 2H), 7.22-7.15 (m, 3H), 5.83 (dddd, J = 6.5, 6.5, 10.3, 16.8 Hz, 1H), 5.05 
(dd, J = 1.0, 17.1 Hz, 1H), 4.99 (dd, J = 1.0, 10.3 Hz, 1H), 3.47-3.38 (m, 2H), 2.72-2.57 
(m, 2H), 2.08 (br s, 2H), 1.90-1.76 (m, 1H), 1.76-1.64 (m, 1H), 1.63-1.43 (m, 4H); 13C 
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NMR (100 MHz, CDCl3) δ 142.1, 138.2, 128.4, 128.3, 125.8, 115.0, 74.3, 73.8, 35.8, 






trans-(5-Phenethyltetrahydrofuran-2-yl)-methanol (2.27b). To a solution of 2.27a 
(190 mg, 1.0 mmol, 1.0 eq) in i-PrOH (10 mL) under an atmosphere of O2 was added 
Co(Modp)2 (54 mg, 0.10 mmol, 0.10 eq) and t-BuOOH (0.28 mL, 3.57 M, 1.0 mmol, 1.0 
eq) at rt. The reaction mixture was heated to 50 °C for 24 h and allowed to cool to rt. 
Concentration and purification of the residue by flash chromatography on SiO2 (elution 
gradient: 25% EtOAc/hexanes to 30% EtOAc/hexanes) provided the title compound as a 
colorless liquid (170 mg, 82%): Rf 0.17 (30% EtOAc/hexanes); 1H NMR (400 MHz, 
CDCl3) δ 7.35-7.25 (m, 2H), 7.24-7.15 (m, 3H), 4.14 (dddd, J = 6.8, 10.0, 10.0, 10.0 Hz, 
1H), 3.95 (dddd, J = 6.8, 6.8, 6.8, 6.8 Hz, 1H), 3.66 (app d, J = 10.4 Hz, 1H), 3.49 (dd, J 
= 6.0, 10.4 Hz, 1H), 2.75 (ddd, J = 5.6, 10.0, 14.0 Hz, 1H), 2.65 (ddd, J = 6.4, 9.6, 14.0 
Hz, 1H), 2.09-1.85 (m, 4H), 1.81-1.51 (m, 3H); 13C NMR (100 MHz, CDCl3) δ 141.9, 
128.28, 128.26, 125.7, 78.9, 78.6, 64.9, 37.3, 32.4, 31.9, 24.4; HRMS m/z 205.1224 







trans-5-Phenethyltetrahydrofuran-2-carbaldehyde (2.103). A solution of DMSO (0.40 
mL, 6.0 mmol) in CH2Cl2 (2 mL) was added dropwise to a -78 °C solution of oxalyl 
chloride (0.23 mL, 2.7 mmol) in CH2Cl2 (10 mL). After 30 min, a solution of alcohol 
2.18b (210 mg, 1.0 mmol) in CH2Cl2 (2 mL) was added dropwise to the reaction mixture. 
After 45 min, Et3N (1.3 mL, 9 mmol) was added and the reaction mixture was allowed to 
warm to rt. The organic layer was washed with water and brine, dried (MgSO4), filtered 
and concentrated. Purification of the residual oil by flash chromatography on SiO2 
(elution gradient: 30% EtOAc/hexanes to 40% EtOAc/hexanes) provided the title 
compound as a colorless oil (184 mg, 0.90 mmol, 89%): Rf 0.15 (30% EtOAc/hexanes); 
1H NMR (400 MHz, CDCl3) δ 9.67 (d, J = 2.1 Hz, 1H), 7.32-7.25 (m, 2H), 7.24-7.17 (m, 
3H), 4.35 (ddd, J = 2.1, 6.8, 8.5 Hz, 1H), 4.03 (dddd, J = 5.5, 5.5, 7.9, 7.9 Hz, 1H), 2.79 
(ddd, J = 5.5, 9.6, 13.7 Hz, 1H), 2.70 (ddd, J = 6.5, 9.6, 13.7 Hz, 1H), 2.25-2.16 (m, 2H), 
2.08-1.91 (m, 3H), 1.87-1.77 (m, 1H), 1.63-1.53 (m, 1H); 13C NMR (100 MHz, CDCl3) δ 





trans-1-(5-Phenethyltetrahydrofuran-2-yl)-propan-1-ol (2.29b). The title compound 
was prepared as a mixture of syn/anti diastereomers (dr: 1.2:1) from the corresponding 
cis-alkene (218 mg, 1.0 mmol) according to the general procedure described for 2.27b 
(colorless liquid, 165 mg, 71%). 
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The title compound was also prepared as a mixture of syn/anti diastereomers (dr: 1.3:1) 
from the corresponding trans-alkene (218 mg, 1.0 mmol) according to the general 
procedure described for 2.27b (colorless liquid, 125 mg, 53%). 
 
The title compound was also prepared as a mixture of syn/anti diasteromers (dr: 2:1) by 
dropwise addition of EtMgBr (1.0 mL, 3.0 M in Et2O, 3.0 mmol) to a solution of 
aldehyde 2.103 (160 mg, 0.78 mmol) in Et2O at 0 °C. After 1 h, aqueous NH4Cl (5 mL, 
50% sat’d) was added dropwise, the reaction mixture was allowed to warm to rt and the 
layers were separated. The aqueous layer was extracted with Et2O and the combined 
extracts were washed with brine, dried (MgSO4), filtered and concentrated. The crude 
material was purified by flash chromatography on SiO2 (elution gradient: 25% 
EtOAc/hexanes to 30% EtOAc/hexanes), providing the title compound as a colorless 




syn isomer: Rf 0.43 (30% EtOAc/hexanes); 1H NMR (400 MHz, CDCl3) δ 7.33-7.25 (m, 
2H), 7.24-7.16 (m, 3H), 3.91 (dddd, J = 5.5, 5.5, 7.9, 7.4 Hz, 1H), 3.83 (ddd, J = 6.8, 6.8, 
6.8 Hz, 1H), 3.32 (ddd, J = 3.8, 6.8, 7.9 Hz, 1H), 2.80-2.62 (m, 2H), 2.48 (br s, 1H), 2.08-
1.86 (m, 3H), 1.84-1.72 (m, 1H), 1.69-1.35 (m, 4H), 1.01 (dd, J = 7.5, 7.5 Hz, 3H); 13C 
NMR (100 MHz, CDCl3) δ 142.0, 128.33, 128.28, 125.7, 125.7, 81.6, 78.4, 75.4, 37.2, 
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anti isomer: Rf 0.40 (30% EtOAc/hexanes); 1H NMR (400 MHz, CDCl3) δ 7.31-7.25 (m, 
2H), 7.22-7.15 (m, 3H), 4.02-3.91 (m, 2H), 3.73 (ddd, J = 5.1, 8.5, 2.8 Hz, 1H), 2.75 
(ddd, J = 5.8, 10.3, 14.0 Hz, 1H), 2.65 (ddd, J = 6.5, 9.6, 13.7 Hz), 2.14-2.02 (m, 2H), 
1.96-1.80 (m, 3H), 1.80-1.70 (m, 1H), 1.61-1.50 (m, 1H), 1.49-1.38 (m, 2H), 1.00 (dd, J 
= 7.5, 7.5 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 142.0, 128.33, 128.30, 81.2, 79.2, 







trans-(2-Methyl-5-phenethyltetrahydrofuran-2-yl)-methanol (2.28b). The title 
compound was prepared from alkene 2.28a (204 mg, 1.0 mmol) according to the general 
procedure described for 2.27b (colorless liquid, 165 mg, 75%): Rf 0.30 (30% 
EtOAc/hexanes); 1H NMR (300 MHz, CDCl3) δ 7.35-7.27 (m, 2H), 7.25-7.17 (m, 3H), 
3.96 (dddd, J = 6.6, 6.6, 6.6, 6.6 Hz, 1H), 3.46 (s, 2H), 2.82-2.62 (m, 2H), 2.23 (br s, 1H), 
2.10-1.90 (m, 3H), 1.90-1.62 (m, 3H), 1.25 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 142.0, 
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128.3, 125.7, 82.9, 79.4, 68.5, 38.0, 33.5, 32.3, 31.8, 24.5; HRMS m/z 221.1544 (calc’d 













(5R,6R)-5,6-dihydroxy-1,9-decadiene (2.23a). A suspension of CuI (3.17 g, 17.8 mmol) 
in THF (53 mL) was cooled to −30 °C (bromobenzene/CO2 bath). To this suspension, 
allylmagnesiumbromide (175 mL, 1.0 M in Et2O, 175 mmol) was added dropwise. After 
1 h, bis-epoxide 2.42 (6.29 g, 73.1 mmol) in THF (18 mL) was added dropwise. After 1h, 
the cooling bath was replaced with an ice bath and aqueous NH4Cl (sat’d, 900 mL) was 
slowly added. After 30 min, the layers were separated and the aqueous layer was 
extracted with CH2Cl2. The organic layers were combined, dried (MgSO4), filtered and 
concentrated in vacuo. Distillation under reduced pressure (82-88 °C, 0.4 mm Hg) 
provided the title compound as a colorless oil (10.0 g, 58.9 mmol, 81%): Rf  0.81 
(EtOAc); 1H NMR (300 MHz, CDCl3) δ 5.93-5.80 (m. 2H). 5.12-4.99 (m, 4H), 3.49-3.40 
(m, 2H), 2.32-2.05 (m, 4H), 1.65-1.56 (m, 4H); 13C NMR (100 MHz, CDCl3) δ 138.3, 





(5R,6R)-5-acetoxy-6-hydroxydeca-1,9-diene (2.43a). To a solution of diol 2.23a (1.87 
g, 11.0 mmol) in CH2Cl2 (22 mL) was added triethyl orthoacetate (6.0 mL, 33.0 mmol) 
and TsOH•H2O (21 mg, 0.11 mmol) at rt. After 10 h, the reaction mixture was 
concentrated in vacuo, the residue was dissolved in CH2Cl2 (15 mL) and treated with 
aqueous AcOH (8 mL, 80%) at rt. After 1 h, the layers were separated, the aqueous layer 
was extracted with CH2Cl2 and the combined extracts were washed with NaHCO3 (sat’d), 
H2O, and brine. The organic layers were dried (MgSO4), filtered and concentrated in 
vacuo. Purification by flash chromatography on SiO2 (elution gradient: 14% 
EtOAc/hexanes to 25% EtOAc/hexanes) provided the title compound as a colorless oil 
(2.31 g, 11.0 mmol, 99%): Rf  0.17 (20% EtOAc/hexanes); 1H NMR (400 MHz, CDCl3) δ 
5.78 (dddd, J = 6.5, 6.5, 10.3, 16.8 Hz, 2H), 5.06-4.92 (m, 4H), 4.84 (ddd, J = 3.8, 5.8, 
7.5 Hz, 1H) 3.60 (ddd, J = 4.4, 4.4, 7.5 Hz, 1H), 2.27-2.09 (m, 2H), 2.09-2.01 (m, 2H), 
2.07 (s, 3H), 1.80-1.65 (m, 3H), 1.57-1.43 (m, 2H); 13C NMR (100 MHz, CDCl3) 
δ 170.9, 138.0, 137.5, 115.21, 115.17, 75.9, 71.8, 32.7, 29.83, 29.77, 29.6, 21.0 (calc’d 










(2.23b). The title compound was prepared from diol 2.23a (170 mg, 1.0 mmol) according 
to the general procedure described for 2.27b except 1% (v/v) H2O was added to the 
reaction mixture (colorless liquid, 91 mg, 45%): The 1H and 13C NMR spectra of this 
compound were in agreement with published values.55a-b 
 
The title compound was also prepared from the corresponding mono-THF alkene 2.45a 








(2.43b). The title compound was prepared from alkene 2.43a (2.40 g, 11.3 mmol) 
according to the general procedure described for 2.27b (colorless liquid, 2.11 g, 82%): Rf 
0.20 (60% EtOAc/hexanes); 1H NMR (400 MHz, CDCl3) δ 5.75 (dddd, J = 6.4, 6.4, 10.0, 
16.9 Hz, 1H), 5.02-4.87 (m, 2H), 4.86 (ddd, J = 5.4, 5.4, 8.2 Hz, 1H, ), 4.10-3.94 (m 2H), 
3.62 (dd, J = 3.3, 11.8 Hz, 1H) 3.44 (dd, J = 5.6, 11.8 Hz, 1H), 2.16 (br s, 1H), 2.09-1.82 
(m, 4H), 2.05 (s, 3H), 1.75-1.54 (m, 4H); 13C NMR (100 MHz, CDCl3) δ 170.8, 137.5, 
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115.1, 79.7, 79.6, 74.6, 64.5, 30.1, 29.6, 28.2, 27.3, 21.1; HRMS m/z 229.1445 (calc’d for 






(1R)-1-[(2R,5R)-5-hydroxymethyltetrahydrofuran-2-yl]-pent-4-en-1-ol (2.45a). To a 
solution of acetate 2.43b (680 mg, 3.0 mmol) in MeOH (30 mL) was added NaOH (29 
mg, 0.72 mmol) at 0 ºC. The reaction mixture was stirred for 2 h, diluted with water (75 
mL) and extracted with EtOAc. The combined extracts were washed with brine, dried 
(MgSO4), filtered and concentrated. Purification of the residue by flash chromatography 
on SiO2 (elution gradient: 70% EtOAc/hexanes to EtOAc) provided the title compound as 
a colorless oil (452 mg, 81%): Rf 0.19 (70% EtOAc/hexanes); 1H NMR (400 MHz, 
CDCl3) δ 5.84-5.75 (m, 1H), 4.99 (dddd, J = 1.7, 1.7, 1.7, 17.1 Hz, 1H), 4.92 (dddd, J = 
1.0, 2.0, 3.1, 10.3 Hz, 1H), 4.09-4.00 (m, 1H), 3.79 (ddd, J = 7.0, 7.0, 7.0 Hz, 1H), 3.66-
3.55 (m, 1H), 3.50-3.34 (m, 2H), 3.22 (br s, 1H), 3.09 (br s, 1H), 2.30-2.18 (m, 1H), 2.17-
2.04 (m 1H), 2.02-1.85 (m 2H), 1.72-1.52 (m, 2H), 1.52-1.39 (m, 2H); 13C NMR (100 
MHz, CDCl3) δ 138.3, 114.8, 82.9, 79.9, 73.4, 64.7, 32.5, 29.7, 28.5, 27.8; HRMS m/z 









pent-4-ene (4.77). To a solution of alcohol 2.43b (5.49 g, 24.1 mmol) in DMF (30 mL) 
was added imidazole (4.49 g, 66.1 mmol) and TBSCl (4.49 g, 29.9 mmol) at rt. After 16 
h, the reaction mixture was diluted with Et2O and washed with H2O and brine, dried 
(MgSO4) and concentrated. Purification by flash chromatography on SiO2 (elution 
gradient: 2.5% EtOAc/hexanes to 10% EtOAc/hexanes) provided the title compound as a 
colorless oil (7.7 g, 22.5 mmol, 94%): Rf 0.17 (8% EtOAc/Hexanes); 1H NMR (400 MHz, 
CDCl3) δ 5.75 (dddd, J = 6.7, 6.7, 10.2, 16.9 Hz, 1H), 4.97 (dddd, J = 1.6, 1.6, 1.6, 16.9 
Hz, 1H), 4.92 (dddd, J = 1.3, 1.3, 1.3 Hz, 1H), 4.86 (ddd, J = 5.1, 5.1, 8.5 Hz, 1H), 4.07-
3.95 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 170.8, 137.7, 115.0, 79.8, 79.6, 74.7, 65.6, 








ol (2.18a). To a 0 ºC solution of 4.77 (4.10 g, 12.0 mmol) in Et2O (14 mL) was slowly 
added EtMgBr (13.2 mL, 2.78 M in Et2O, 36.7 mmol). After 1 h, aqueous HCl (80 mL, 
0.5 M, 40 mmol) was added dropwise. The layers were separated and the organic layer 
was washed with HCl (50 mL, 0.5 M) and brine, dried (MgSO4), filtered and 
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concentrated. Purification by flash chromatography on SiO2 (elution gradient: 5% 
EtOAc/hexanes to 13% EtOAc/hexanes) provided the title compound as a colorless oil 
(3.56 g, 11.9 mmol, 99%): Rf 0.20 (10% EtOAc/hexanes); 1H NMR (400 MHz, CDCl3) δ 
5.80 (dddd, J = 6.7, 6.7, 10.2, 16.9 Hz, 1H), 5.01 (dddd, J = 1.5, 1.5, 1.5, 16.9 Hz, 1H), 
4.93 (dddd, J = 1.3, 1.3, 2.3, 2.3 Hz, 1H), 4.01 (ddd, J = 4.9, 5.9, 12.3 Hz, 1H), 3.79 (ddd, 
J = 6.1, 6.4, 7.7 Hz, 1H), 3.60 (dd, J = 4.9, 10.8 Hz, 1H), 3.55 (dd, J = 2.8, 10.8 Hz, 1H), 
3.37 (ddd, J = 5.9, 6.4, 6.4 Hz, 1H), 2.34-2.04 (m, 3H), 2.02-1.87 (m, 2H), 1.81-1.52 (m, 
2H), 1.52-1.42 (m, 2H), 0.86 (s, 9H), 0.03 (s, 6H); 13C NMR (75 MHz, CDCl3) δ 138.5, 
114.7, 82.6, 79.7, 73.3, 65.8, 32.8, 29.8, 28.3, 28.2, 25.9, 18.3, -5.3; HRMS m/z 301.2200 






yl]-methanol (2.18b). The title compound was prepared from alkene 2.18a (3.12g, 10.4 
mmol) according to the general procedure described for 2.27b (colorless liquid, 2.60 g, 
79%): Rf 0.32 (50% EtOAc:hexanes); 1H NMR (400 MHz, CDCl3) δ 4.13-4.03 (m, 2H), 
3.90-3.85 (m, 2H), 3.70-3.65 (m, 2H), 3.60 (dd, J = 5.6, 10.0 Hz, 1H), 3.47 (dd, J = 4.8, 
11.6 Hz, 1H), 2.23 (brs, 1H), 2.04-1.90 (m, 4H), 1.79-1.53 (m, 4H), 0.87 (s, 9H), 0.03 (s, 
6H); 13C NMR (100 MHz, CDCl3) δ 82.23, 82.20, 79.82, 79.80, 65.8, 64.5, 28.7, 28.39, 









The title compound was prepared from alkene 2.46a (234 mg, 1.0 mmol) according to the 
general procedure described for 2.27b (colorless liquid, 184 mg, 74%): Rf 0.21 (70% 
EtOAc/hexanes); 1H NMR (400 MHz, CDCl3) δ 7.27, (dd, J = 7.5, 7.5 Hz, 2H), 7.21-7.14 
(m, 3H), 4.12-4.04 (m, 1H), 3.81 (ddd, J = 7.2, 7.2, 7.2 Hz, 1H), 3.65 (dd, J = 2.7, 12.0 
Hz, 1H), 3.49 (dd, J = 6.7, 12.0 Hz, 1H), 3.44 (ddd, J = 6.5, 6.5, 6.5 Hz, 1H), 2.88 (s, 2) 
2.71-2.56 (m, 2H), 2.00-1.82 (m, 3H), 1.78-1.55 (m, 3H), 1.44 (app ddd, J = 7.9, 7.9, 7.9 







(4-Benzyltetrahydrofuran-2-yl)-methanol (2.33b). The title compound was prepared as 
an inseparable mixture of cis/trans diastereomers (dr: 1.7:1) from alkene 2.33a (176 mg, 
1.0 mmol) according to the general procedure described for 2.27b (colorless liquid, 159 
mg, 83%): 
cis isomer: 
Rf 0.15 (30% EtOAc/hexanes); 1H NMR (400 MHz, CDCl3) δ 7.28-7.17 (m, 2H), 7.16-
7.05 (m, 3H), 4.22-3.93 (m, 1H), 3.84-3.74 (m, 1H), 3.80 (dd, J = 7.5, 7.5 Hz, 1H), 3.58-
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3.43 (m, 2H), 2.77-2.49 (m, 4H), 1.96 (ddd, J = 6.5, 6.5, 12.3 Hz, 1H), 1.74 (ddd, J = 8.9, 
8.9, 12.3 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 140.4, 128.6, 128.3, 126.0, 80.2, 72.9, 
64.7, 41.6, 39.0, 33.8; HRMS m/z 193.1227 (calc’d for C12H17O2 [M+H]+, 193.1229). 
trans isomer: 
Rf 0.15 (30% EtOAc/hexanes); 1H NMR (400 MHz, CDCl3) δ 7.28-7.17 (m, 2H), 7.16-
7.05 (m, 3H), 4.15-4.06 (m, 1H), 3.88 (dd, J = 7.9, 7.9 Hz, 1H), 3.71 (m, 1H), 3.58-3.43 
(m, 2H), 2.74-2.45 (m, 4H), 1.77 (ddd, J = 6.8, 6.8, 12.7 Hz, 1H), 1.66 (ddd, J = 7.9, 7.9, 
13.3 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 140.4, 128.6, 128.5, 126.0, 79.0, 73.1, 65.0, 






(3-Phenyltetrahydrofuran-2-yl)-methanol (2.37b). The title compound69 was prepared 
from alkene 2.37a (162 mg, 1.0 mmol) according to the general procedure described for 
2.27b (colorless liquid, 134 mg, 75%): Rf 0.20 (30% EtOAc/hexanes); 1H NMR (400 
MHz, CDCl3) δ 7.35-7.30 (m, 2H), 7.29-7.19 (m, 3H), 4.12 (ddd, J = 4.1, 8.2, 12.7 Hz, 
1H), 4.01 (ddd, J = 6.8, 8.2, 8.2 Hz, 1H), 3.94 (ddd, J = 2.7, 5.1, 8.2 Hz, 1H), 3.75, (dd, J 
= 2.7, 12.0 Hz, 1H), 3.54 (dd, J = 5.1, 12.0 Hz, 1H), 3.20 (ddd, J = 8.5, 8.5, 8.5 Hz, 1H), 
2.45 (br s, 1H), 2.43-2.34 (m, 1H), 2.23-2.12 (m 1H); 13C NMR (100 MHz, CDCl3) δ 
141.1, 128.6, 127.6, 126.7, 86.3, 68.2, 62.7, 46.0, 35.4; HRMS m/z 179.1070 (calc’d for 






(5-Hydroxymethylhexahydrofuro[3,2-b]furan-2-yl)-methanol (2.41b). The title 
compound was prepared from diol 2.41a (170 mg, 1.0 mmol) according to the general 
procedure described for 2.27b except 1% (v/v) H2O was added to the reaction mixture 
(79 mg, 50%): Rf 0.31 (10% MeOH/CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 4.69 (d, J = 
4.4 Hz, 2H), 4.17 (dddd, J = 2.1, 5.5, 5.5, 9.9 Hz, 2H), 3.71 (dd, J = 2.1, 12.0 Hz, 2H), 
3.44 (dd, J = 5.5, 12.0 Hz, 2H), 2.50 (br s, 2H), 2.04 (dd, J = 5.5, 13.3 Hz, 2H), 1.83 (ddd, 
J = 4.4, 9.9, 13.3 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ; HRMS m/z 175.0974 (calc’d 
for C8H15O4 [M+H]+, 175.0970). 






carbaldehyde (4.78). A solution of DMSO (1.2 mL, 18 mmol) in CH2Cl2 (4.7 mL) was 
added dropwise to a -78 °C solution of oxalyl chloride (0.69 mL, 8.0 mmol) in CH2Cl2 
(36 mL). After 30 min, a solution of alcohol 2.18b (0.95 g, 3.0 mmol) in CH2Cl2 (4.7 
mL) was added dropwise to the reaction mixture. After 45 min, Et3N (3.8 mL, 27 mmol) 
was added and the reaction mixture was allowed to warm to rt. The organic layer was 
washed with water and brine, dried (Na2SO4), filtered and concentrated. Purification of 
the residual oil by flash chromatography on SiO2 (elution gradient: 20% EtOAc/hexanes 
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to 30% EtOAc/hexanes) provided the title compound as a colorless oil (0.91 g, 2.9 mmol, 
96%): Rf 0.42 (5% MeOH/CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 9.68 (d, J = 2.0 hz, 
1H), 4.36-4.31 (m, 1H), 4.11-3.99 (m, 2H), 3.96-3.91 (m, 1H), 3.67 (dd, J = 4.0, 10.4 Hz, 
1H), 3.58 (dd, J = 5.2, 10.4 Hz, 1H), 2.24-2.17 (m, 1H), 2.07-1.89 (m, 4H), 1.82-1.65 (m, 
3H), 0.88 (s, 9H), 0.04 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 203.1, 83.4, 83.2, 81.7, 








ynyl]octahydro-[2,2’]bifuran (4.79). To a 0 °C solution of 1-decyne (2.1 mL, 12 mmol) 
in Et2O (40 mL), n-BuLi (4.8 mL 2.4 M solution in hexanes, 12 mmol) was added 
dropwise. After cooling the reaction mixture to −78 °C, TiCl(Oi-Pr)3 (5.1 mL 2.26 M 
solution in toluene, 12 mmol) was added dropwise. After 30 min, a solution of aldehyde 
4.78 (0.78 g, 2.5 mmol) in Et2O (10 mL) was added dropwise. The reaction mixture was 
allowed to warm up to 0 °C over 1 h and after 8 h, an aqueous solution of tartaric acid 
(100 mL, 1.0 M, 100 mmol) was added to the reaction mixture and the ice bath was 
removed. After 1 h at rt, the layers were separated and the aqueous layer was extracted 
with EtOAc. The combined organic layers were dried (Na2SO4), filtered and 
concentrated. Purification of the residue by flash chromatography on SiO2 (elution 
gradient: 14% EtOAc/hexanes to 25% EtOAc/hexanes) provided the title compound as an 
 120
inseparable mixture of epimers (0.90 g, 2.0 mmol, 82%): Rf 0.25 (25% EtOAc/hexanes); 
1H NMR (400 MHz, CDCl3) δ 4.52 (m, 1H), 4.16-4.10 (m, 1H), 4.10-4.01 (m, 1H), 4.02-
3.94 (m, 1H), 3.92-3.82 (m, 1H), 3.67 (dd, J = 4.0, 10.4 Hz, 1H), 3.55 (dd, J = 6.0, 10.4 
Hz, 1H), 2.38 (brs, 1H), 2.17 (dt, J = 2.0, 6.8 Hz, 2H), 2.06-1.90 (m, 5H), 1.82-1.70 (m, 
1H), 1.70-1.54 (m, 2H), 1.54-1.40 (m, 2H), 1.40-1.22 (m, 10H), 0.87 (s, 9H), 0.86 (dd, J 
= 6.8, 6.8 Hz, 3H), 0.03 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 86.5, 83.4, 82.3, 82.1, 
79.8, 77.6, 65.8, 63.9, 38.0, 31.8, 29.1, 29.0, 28.8, 28.6, 28.5, 28.4, 28.3, 25.9, 22.6, 18.7, 








hydroxytriundecanyl]octahydro-[2,2’]bifuran (4.80) To a solution of the 
diastereomeric mixture of 4.79 (0.90 g, 2.0 mmol) in benzene (20 mL) was added Pd/C 
(10% by wt, 0.20 g, 0.20 mmol). The mixture was stirred under 1 atm of H2 for 8 h. The 
reaction mixture was filtered (Celite) and concentrated, and the residue was purified by 
flash chromatography on SiO2 (elution gradient: 15% EtOAc/hexanes to 30% 
EtOAc/hexanes), providing the title compound (789 mg, 1.7 mmol, 85%) and its epimer 






OH 4.80a  
4.80a: Rf 0.25 (25% EtOAc/hexanes); 1H NMR (400 MHz, CDCl3) δ 4.13-4.04 (m, 1H), 
3.94-3.84 (m, 4H), 3.70 (dd, J = 3.9, 10.5 Hz, 1H), 3.56 (dd, J = 6.0, 10.2 Hz, 1H), 2.05-
1.71 (m, 7H), 1.64-1.40 (m, 3H), 1.32-1.22 (m, 16H), 0.87 (s, 9H), 0.86 (t, J = 6.8 Hz, 
3H), 0.03 (s, 6H); 13C NMR (63 MHz, CDCl3) δ 82.51, 82.46, 79.8, 71.1, 65.8, 32.4, 
31.9, 29.64, 29.55, 29.5, 29.3, 28.7, 28.4, 28.3, 26.0, 25.9, 24.4, 22.6, 18.2, 14.1, -5.4; 




OH 4.80b  
4.80b: Rf 0.30 (25% EtOAc/hexanes); 1H NMR (400 MHz, CDCl3) δ 4.10-4.03 (m, 1H), 
3.92-3.78 (m, 3H), 3.66 (dd, J = 4.4, 10.8 Hz, 1H), 3.56 (dd, J = 6.4, 10.4 Hz, 1H), 3.40-
3.34 (m, 1H), 2.27 (brs, 1H), 2.04-1.90 (m, 4H), 1.80-1.58 (m, 4H), 1.58-1.20 (m, 18H), 
0.87 (s, 9H), 0.86 (dd, J = 6.9, 6.9 Hz, 3H), 0.04 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 
82.9, 82.0, 81.9, 79.9, 74.0, 65.8, 33.4, 31.9, 29.7, 29.59, 29.57, 29.3, 28.8, 28.5, 28.32, 
28.31, 25.9, 25.6, 22.6, 18.3, 14.1, -5.3. 
 
Relative stereochemistry was assigned by Swern oxidation of the mixture and L-
Selectride® reduction.100  The 1H NMR and 13C NMR spectra of the major threo epimer 










benzyloxytriundecanyl]octahydro-[2,2’]bifuran (4.104). A solution of alcohol 4.80a 
(726 mg, 1.59 mmol) in DMF (1 mL) was added to a suspension of NaH (60%, 190 mg, 
4.7 mmol) in DMF (9 mL) at 0 °C. After stirring for 15 min, benzyl bromide (598 mg, 
3.5 mmol) and Bu4NI (29.4 mg, 0.08 mmol) were added. After 16 h, the reaction mixture 
was diluted with Et2O and washed with H2O and brine. The organic fraction was 
separated, dried (MgSO4), filtered and concentrated. Purification of the residue by flash 
chromatography on SiO2 (elution gradient: 2% EtOAc/hexanes to 8% EtOAc/hexanes) 
provided the title compound as a colorless oil (800 mg, 1.5 mmol, 92%): Rf 0.35 (5% 
EtOAc/hexanes); 1H NMR (300 MHz, CDCl3) δ 7.38−7.22 (m, 5H), 4.73 (d, J = 11.7 Hz, 
1H), 4.58 (d, J = 11.4 Hz, 1H), 4.16-3.99 (m, 2H), 3.96-3.85 (m, 2H), 3.70 (dd, J = 4.2, 
10.2 Hz, 1H), 3.66-3.59 (m, 1H), 3.55 (dd, J = 5.7, 10.2 Hz, 1H), 2.08-1.86 (m, 5H), 
1.82-1.56 (m, 3H), 1.52-1.37 (m, 3H), 1.36-1.19 (m, 16H), 0.89 (s, 9H), 0.88 (dd, J = 6.9, 
6.9 Hz, 3H), 0.06 (s, 6H); 13C NMR (75 MHz, CDCl3) δ 139.4, 128.2, 127.7, 127.3, 82.5, 
82.0, 81.8, 80.7, 79.8, 73.3, 65.9, 32.0, 31.9, 29.7, 29.59, 29.57, 29.3, 28.7, 28.5, 28.3, 










[2,2’]bifuran (4.105).  A solution of 4.104 (869 mg, 1.59 mmol) in MeOH (10 mL) and 
HCl (3.4 mL, 7.0 M solution in MeOH, 24 mmol) was added at rt. After 2 h, the mixture 
was concentrated and purification of the residue by flash chromatography on silica gel 
(elution gradient: CH2Cl2 to 2% MeOH/CH2Cl2) provided the title compound as colorless 
oil (674 mg, 1.56 mmol, 98%): Rf 0.54 (5% MeOH/DCM); 1H NMR (400 MHz, CDCl3) 
δ 7.36−7.24 (m, 5H), 4.73 (d, J = 11.1 Hz, 1H), 4.59 (d, J = 11.4 Hz, 1H), 4.16-4.01 (m, 
2H), 3.95-3.85 (m, 2H), 3.76-3.62 (m, 2H), 3.50 (dd, J = 5.1, 11.7 Hz, 1H), 2.39 (brs, 
1H), 2.02-1.85 (m, 5H), 1.80-1.52 (m, 3H), 1.52-1.36 (m, 3H), 1.36-1.18 (m, 15H), 0.87 
(dd, J = 7.2, 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ: 139.2, 128.1, 127.6, 127.2, 
82.6, 82.1, 81.9, 80.5, 79.8, 73.3, 64.5, 31.9, 31.8, 29.6, 29.49, 29.47, 29.2, 28.7, 27.4, 








carbaldehyde (4.84). The title compound was prepared according to the procedure 
described for 4.78 as a yellow oil (651 mg, 1.51 mmol, 97%): Rf 0.39 (2.5% 
MeOH/CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 9.70 (d, J = 0.8 Hz, 1H), 7.39-7.23 (m, 
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5H), 4.73 (d, J = 11.1 Hz, 1H), 4.59 (d, J = 11.4 Hz, 1H), 4.35 (t, J = 6.4 Hz, 1H), 4.10-
3.98 (m, 2H), 3.97-3.90 (m, 1H), 3.67-3.61 (m, 1H), 2.27-2.16 (m, 1H), 2.06-1.88 (m, 
5H), 1.78-1.62 (m, 2H), 1.52-1.37 (m, 3H), 1.34-1.19 (m, 16H), 0.88 (dd, J = 7.2, 7.2 Hz, 
3H); 13C NMR (100 MHz, CDCl3) δ 203.0, 139.3, 128.2, 127.7, 127.3, 83.4, 83.3, 82.8, 
81.4, 80.6, 73.3, 32.0, 31.9, 29.7,  29.6, 29.3, 28.8, 28.0, 27.3, 26.0, 25.8, 22.6, 14.1; 










benzyloxyundecyl]octahydro-[2,2’]bifuran (4.85).  The title compound was prepared as 
a mixture of erythro/threo isomers from aldehyde 4.84 (645 mg, 1.17 mmol) and bromide 
4.82 (2.73 g, 9.0 mmol) using the general procedure described for 4.96 (colorless oil, 770 








4.85a: Rf 0.29 (20% EtOAc/hexanes); 1H NMR (300 MHz, CDCl3) δ 7.37-7.29 (m, 4H), 
7.28-7.22 (m, 1H), 4.71 (d, J = 11.6 Hz, 1H), 4.59 (d, J =11.6 Hz, 1H), 4.05 (ddd, J = 3.4, 
6.8, 6.8 Hz, 1H), 3.93-3.85 (m, 2H), 3.82 (ddd, J = 6.8, 6.8, 6.8 Hz, 1H), 3.62 (ddd, J = 
4.1, 4.1, 7.5 Hz, 1H), 3.54 (ddd, J = 4.1, 4.1, 6.8 Hz, 1H), 2.45 (br s, 1H), 2.19 (dd, J = 
7.2, 7.2 Hz, 2H), 2.01-1.88 (m, 5H), 1.73-1.55 (m, 3H), 1.55-1.17 (m, 32H), 0.88 (dd, J = 
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6.5, 6.5 Hz, 3H), 0.14 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 139.2, 128.2, 127.7, 127.2, 
107.7, 84.1, 82.9, 82.6, 81.9, 81.7, 80.5, 73.9, 73.3, 33.4, 31.89, 31.85, 29.7, 29.6, 29.53, 
29.48, 29.4, 29.3, 29.0, 28.8, 28.7, 28.6, 28.3, 26.1, 25.7, 25.6, 22.6, 19.8, 14.1, 0.1; 








4.85b: Rf 0.24 (20% EtOAc/hexanes); 1H NMR (300 MHz, CDCl3) δ 7.36-7.20 (m, 5H), 
4.71 (d, J = 11.8 Hz, 1H), 4.57 (d, J = 11.8 Hz, 1H), 4.04 (ddd, J = 3.3, 3.3, 6.7 Hz, 1H), 
3.94-3.81 (m, 4H), 3.62 (ddd, J = 6.7, 6.7 Hz, 1H), 2.18 (ddd, J = 1.8, 6.9, 6.9 Hz, 2H), 
2.01-1.70 (m, 8H), 1.64-1.16 (m, 32H), 0.86 (dd, J = 6.7, 6.7 Hz, 3H), 0.12 (s, 9H); 13C 
NMR (75 MHz, CDCl3) δ 139.6, 128.5. 127.6, 108.03, 108.00, 107.99, 84.5, 83.0, 82.8, 
82.5, 80.9, 73.7, 71.4, 63.3, 30.0, 29.9, 29.8, 29.73, 29.67, 29.6, 29.32, 29.25, 29.05, 
29.00, 28.88, 28.85, 26.3, 26.1, 26.0, 22.9, 20.1, 14.4, 0.4; HRMS m/z 655.5115 (calc’d 









benzyloxyundecyl]octahydro-[2,2’]bifuran (4.106).  The title compound was prepared 
from 4.85a (245 mg, 0.38 mmol) using the general procedure for 4.112 (colorless oil, 200 
mg, 92%): Rf 0.27 (20% EtOAc/hexanes); 1H NMR (400 MHz, CDCl3) δ 7.37-7.28 (m, 
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4H), 7.28-7.22 (m, 1H), 4.71 (d, J = 11.6 Hz, 1H), 4.59 (d, J = 11.6 Hz, 1H), 4.05 (ddd, J 
- 3.4, 6.8, 6.8 Hz, 1H), 3.93-3.85 (m, 2H), 3.82 (ddd, J = 7.9, 7.9, 7.9 hz, 1H, 3.61 (ddd, J 
= 3.8, 3.8, 7.5 Hz, 1H), 3.39 (ddd, J = 4.1, 6.8, 6.8 Hz, 1H), 2.45 (br s, 1H), 2.16 (app 
ddd, J = 2.4, 6.8, 6.8 Hz, 2H), 2.01-1.86 (m, 6H), 1.73-1.56 (m, 3H), 1.55-1.21 (m, 34H), 
0.87 (dd, J = 7.2, 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 139.2, 128.1, 127.7, 127.2, 
84.7, 82.9, 82.6, 81.8, 81.7, 80.5, 73.9, 73.2, 68.0, 33.4, 31.85, 31.82, 29.63, 29.62, 29.52, 









benzyloxyundecyl]octahydro-[2,2’]bifuran (4.107). The title compound was prepared 
from 4.106 (200 mg, 0.34 mmol) using the general procedure for 4.97 (colorless oil, 195 
mg, 86%):  Rf 0.24 (10% EtOAc/hexanes); 1H NMR (400 MHz, CDCl3) δ 7.41-7.30 (m, 
8H), 7.30-7.23 (m, 2H), 4.78 (d, J = 11.6, 1H), 4.75 (d, J = 11.6, 1H), 4.62 (app d, J = 
11.6, 2H), 4.16-4.04 (m, 2H), 4.00-3.91 (m, 2H), 3.62 (ddd, J = 3.1, 3.1, 6.8 Hz, 1H), 
3.41 (ddd, J = 7.2, 7.2, 7.2 Hz, 1H), 2.19 (app ddd, J = 2.4, 7.2, 7.2, 2H), 2.05-1.89 (m, 
6H), 1.81-1.62 (m, 3H), 1.58-1.20 (m, 34H), 0.90 (dd, J = 6.5, 6.5 Hz, 3H); 13C NMR 
(100 MHz, CDCl3) δ 139.3, 139.2, 128.13, 128.10, 127.9, 127.7, 127.25, 127.20, 84.6, 
82.4, 81.78, 81.6, 81.4, 81.2, 80.6, 73.1, 72.7, 68.0, 31.9, 31.8, 30.1, 29.7, 29.54, 29.48, 
29.4, 29.3, 29.0, 28.7, 28.6, 28.4, 28.3, 28.1, 26.3, 25.8, 25.7, 22.6, 18.3, 14.1; HRMS 













one (4.88). The title compound was prepared from 4.108 (80 mg, 0.12 mmol) using the 
general procedure for 4.98 (colorless oil, 51 mg, 51%, 78% BRSM): Rf 0.38 (40% 
EtOAc/hexanes); 1H NMR (300 MHz, CDCl3) δ 7.42-7.24 (m, 10H), 7.24 (d, J = 1.3 Hz, 
1H), 5.07 (dq, J = 1.3, 6.9 Hz, 1H), 4.78 (d, J = 11.5 Hz, 1H), 4.74 (J = 11.5 Hz, 1H), 
4.61 (app d, J = 11.5 Hz, 2H), 4.17-4.03 (m, 2H), 4.03-3.90 (m, 3H), 3.63 (ddd, J = 3.8, 
3.8, 7.7 Hz, 1H), 3.45-3.35 (m, 1H), 2.73 (br s, 1H), 2.62 (app dddd, J = 1.5, 1.5, 3.8, 
15.1 Hz, 2H), 2.53 (app dd, J = 7.9, 15.1 Hz, 2H), 2.20 (ddd, J = 2.3, 2.3, 6.9 Hz, 1H), 
2.17 (ddd, J = 2.3, 2.3, 6.9 Hz, 1H), 2.02-1.90 (m, 5H), 1.80-1.61 (m, 3H), 1.57-1.20 (m, 
33H), 1.44 (d, J = 6.9H, 3H), 0.90 (dd, J = 6.9 Hz, 3H); 13C NMR (75 MHz, CDCl3) 
δ 174.4, 152.0,139.3, 139.2, 130.6, 128.2, 128.1, 127.9, 127.7, 127.30, 127.26, 83.8, 82.5, 
81.7, 81.6, 81.5, 81.3, 80.7, 78.0, 75.3, 73.2, 72.7, 68.3, 31.94, 31.86, 30.6, 29.7, 29.6, 
29.4, 29.3, 29.1, 28.90, 28.87, 28.6, 28.3, 28.1, 27.5, 26.3, 25.9, 25.7, 22.6, 19.0, 18.7, 













The title compound was prepared from 4.88 (50 mg, 61 μmol) using the general 
procedure for 4.99 (colorless oil, 35 mg, 90%): Rf 0.50 (80% EtOAc/hexanes); 1H NMR 
(300 MHz, CDCl3) δ 7.21 (d, J = 1.3 Hz, 1H), 5.04 (dq, J = 1.3, 6.7, 1H), 4.02-3.76 (m, 
6H), 3.38 (ddd, J = 5.1, 5.1, 5.1 Hz, 1H), 3.38, (ddd, J = 5.1, 5.1, 5.1 Hz, 1H), 2.68 (br s, 
1H), 2.64-2.44 (m, 3H), 2.39 (dd, J = 2.6, 5.4 Hz, 1H), 2.37 (J = 2.6, 5.9 Hz, 1H), 2.33 (br 
s, 1H), 2.15 (ddd, J = 2.3, 3.3, 6.9 Hz, 1H), 2.13 (ddd, J = 2.3, 2.3, 6.9 Hz, 1H), 2.04-1.91 
(m, 5H), 1.68-1.18 (m, 35H), 1.42 (d, J = 6.7 Hz, 3H), 0.86 (dd, J = 6.9, 6.9 Hz, 3H); 13C 
NMR (75 MHz, CDCl3) δ 174.4, 152.0, 130.6, 83.7, 83.2, 82.8, 82.5, 82.2, 78.0, 75.3, 
74.1, 71.2, 68.3, 33.2, 32.3, 31.9, 31.8, 29.63 29.55, 29.49, 29.46, 29.4, 29.3, 29.0, 28.93, 
28.85, 28.8, 28.4, 27.5, 26.0, 24.4, 22.6, 19.0, 18.7, 14.1; HRMS m/z 647.4885 (calc’d for 










[2,2’]bifuran-5-yl]-2,14-dihydroxytetradecyl}-5-methyl-5H-furan-2-one (4.89). The 
title compound was prepared from 4.109 (25 mg, 39 μmol) using the general procedure 
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for 4.113 (colorless oil, 23 mg, 91%): Rf 0.56 (80% EtOAc/hexanes); 1H NMR (300 
MHz, CDCl3) δ 7.16 (app s, 1H), 5.03 (app a, J = 6.8 Hz, 1H), 3.92-3.75 (m, 6H), 3.37 
(ddd, J = 5.1, 5.1, 5.1 Hz, 1H), 2.60-2.32 (m, 6H), 2.10-1.72 (m, 6H), 1.65-1.18 (m, 
43H), 1.40 (d, J = 6.8 Hz, 3H), 0.84 (dd, J = 6.4 Hz, 3H);13C NMR (75 MHz, CDCl3) 
δ 174.6, 151.8, 131.1, 83.2, 82.7, 82.5, 82.3, 78.0, 74.1, 71.3, 70.0, 37.4, 33.3, 33.2, 31.9, 
29.7, 29.6, 29.54, 29.52, 29.3, 28.95, 28.91, 28.37, 26.02, 26.00, 24.4, 22.6, 19.1, 14.1; 
HRMS m/z 651.5207 (calc’d for C39H71O7 [M+H]+, 651.5200). 
 







[2,2’]bifuran (4.90). To a 0 °C solution of dodecyltriphenylphosphonium bromide 
(2.55g, 5 mmol) in THF (24 mL) was added n-BuLi (1.7 mL, 2.62M, 4.5 mmol) 
dropwise. After 20 min, the reaction mixture was cooled to -78 °C and a solution of 
aldehyde 4.91 (1.25g, 4.0 mmol) in THF (7 mL) was added dropwise via cannula and 
after an additional 30 min, the cooling bath was replaced with an ice bath. The ice bath 
was removed after 1 h and the reaction mixture was allowed to warm to rt. After 12 h, 
NH4Cl (10 mL, sat’d) was added and the resulting mixture was extracted with Et2O. The 
combined extracts were washed with NaHCO3 and brine, dried (Na2SO4) filtered and 
concentrated. The residue was purified by flash chromatography on SiO2 (elution 
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gradient: 2.5% EtOAc/hexanes to 10% EtOAc/hexanes) to give the title compound as a 
colorless liquid (1.45 g, 81%): Rf 0.71 (50% EtOAc/hexanes); 1H NMR (400 MHz, 
CDCl3) δ 5.47-5.36 (m, 2H), 4.68 (ddd, J = 5.8, 7.9, 8.9 Hz, 1H), 4.05 (ddd, J = 6.2, 6.2, 
10.9, 1H), 3.96-3.86 (m, 2H), 3.66 (dd, J = 8.1, 10.3 Hz, 1H), 3.53 (dd, J = 5.8, 10.3 Hz, 
1H), 2.10-1.89 (m, 6H), 1.78-1.61 (m, 3H), 1.59-1.47 (m, 1H), 1.34-1.20 (m, 18H), 0.86 
(s, 9H), 0.85 (dd, J = 5.8, 5.8 Hz, 3H), 0.02 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 
132.0, 130.8, 81.9, 81.3, 79.8, 75.2, 65.9, 33.4, 31.9, 29.7, 29.64, 29.62, 29.59, 29.5, 
29.32, 29.26, 28.8, 28.5, 28.2, 27.7, 25.9, 22.7, 18.3, 14.1, -5.3; HRMS m/z 467.3910 







(4.110). A solution of 4.90 (1.14 g, 2.57 mmol) in THF (26 mL) was cooled to 0 °C  and 
NBu4F (3.1 mL, 1.0 M, 3.1 mmol) was added dropwise. The ice bath was removed and 
after 12 h, the reaction mixture was extracted with EtOAc. The combined extracts were 
washed with NH4Cl and brine, dried (Na2SO4) and concentrated. Purification of the 
residual oil by flash chromatography on SiO2 (elution gradient: 25% EtOAc/hexanes to 
50% EtOAc/hexanes) provided the title compound as a colorless oil (0.84 g, 98%): Rf 
0.32 (50% EtOAc/hexanes); 1H NMR (400 MHz, CDCl3) δ 5.46-5.34 (m, 2H), 4.69 (ddd, 
J = 5.8, 7.5, 8.6, 1H), 4.10 (dddd, J = 3.4, 3.4, 5.1, 8.9 Hz, 1H), 3.95- 3.83 (m, 2H), 3.66 
(dd, J = 3.4, 11.6 Hz, 1H), 3.46 (dd, J = 5.1, 11.6 Hz, 1H), 2.22 (br s, 1H), 2.08-1.86 (m, 
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6H, 1.76-1.47 (m, 4H), 1.38-1.08 (m, 18H), 0.84 (dd, J = 7.1, 7.1 Hz, 3H); 13C NMR (100 
MHz, CDCl3) δ 132.3, 130.9, 110.0, 82.5, 81.9, 80.1, 77.3, 75.7, 64.8, 33.6, 32.2, 30.0, 
29.91, 29.88, 29.87, 29.8, 29.6, 29.5, 29.2, 29.0, 27.9, 27.7, 22.9, 14.4; HRMS m/z 







(4.91). The title compound was prepared from 4.110 (630 mg, 1.9 mmol) using the 
procedure described for 4.78 (560 mg, 89%).Rf 0.41 (50% EtOAc/hexanes); 1H NMR 
(400 MHz, CDCl3) δ 9.65 (d, J = 2.05 Hz, 1H), 5.48-5.33 (m, 2H), 4.69 (ddd, J = 6.2, 8.9, 
8.9 Hz, 1H), 4.32 (ddd, J = 2.05, 6.8, 7.6 Hz, 1H), 4.03 (ddd, J = 6.2, 6.2, 6.2 Hz, 1H), 
3.96 (ddd, J = 6.5, 6.5, 8.2 Hz, 1H), 2.24-2.15 (m, 1H), 2.10-1.85 (m, 7H), 1.82-1.70 (m, 
2H), 1.61-1.50 (m, 1H), 1.34-1.19 (m, 19H), 0.84 (dd, J = 6.8, 6.8 Hz, 3H); 13C NMR 
(100 MHz, CDCl3) δ 202.9, 132.4, 130.4, 83.28, 83.26, 80.9, 75.5, 33.3, 31.9, 29.7, 
29.57, 29.55, 29.5, 29.3, 29.2, 28.9, 27.9, 27.6, 27.4, 22.6, 14.1; HRMS m/z 351.2903 












enyl]octahydro-[2,2’]bifuran (4.96).  To a suspension of Mg (1.0 g, 42 mmol) in Et2O 
was added dibromoethane (0.30 mL, 3.5 mmol) at rt. After the exotherm concluded, a 
solution of alkyl bromide 4.92 (0.96 g, 3.9 mmol) in Et2O (5 mL) was added and the 
reaction mixture was heated to reflux for 1 h. After transferring the solution away from 
excess Mg to a new flask and heating to reflux, a solution of aldehyde 4.91 (320 mg, 1.0 
mmol) in Et2O (4 mL) was added dropwise. After 45 min, the reaction mixture was 
allowed to cool to rt and NH4Cl (5 mL, 50% sat’d) was added. The layers were separated, 
the aqueous layer was extracted with Et2O and the combined extracts were washed with 
brine, dried (Na2SO4) and concentrated. Purification of the residue by flash 
chromatography on SiO2 (10% EtOAc/hexanes) provided the title compound as a mixture 
of anti/syn diastereomers (400 mg, 77%, dr 2:1). 
 
The title compound was also prepared by L-Selectride™ reduction of ketone 4.111. A 
solution of 4.111 (315 mg, 0.61 mmol) in THF (6 mL) was cooled to -100 °C and L-
Selectride™ was added dropwise using a cold finger cooled to -78 °C. After 2 h, the 
internal temperature was allowed to warm to -60 °C and NaOH (2 mL, 2 M, 4 mmol) and 
H2O2 (2 mL, 30%, 19 mmol) were added dropwise. The resulting mixture was extracted 
with EtOAc and the combined extracts were washed with Na2S2O3 (sat’d), NaHCO3 and 
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brine, dried (Na2SO4), filtered and concentrated. Purification of the residue by flash 
chromatography on SiO2 (10% EtOAc/hexanes) provided the title compound as a mixture 







4.96a: Rf 0.59 (50% EtOAc/hexanes); 1H NMR (400 MHz, CDCl3) δ 5.48-5.34 (m, 2H), 
4.68 (ddd, J = 5.5, 8.2, 8.2 Hz, 1H), 3.92 (ddd, J = 5.8, 5.8, 7.9 Hz, 1H), 3.87 (ddd, J = 
5.8, 5.8, 7.9 Hz, 1H), 3.81 (ddd, J = 6.5, 6.5, 6.5 Hz, 1H), 3.36 (ddd, J = 4.1, 7.2, 7.2 Hz, 
1H), 2.29 (br s, 1H), 2.18 (dd, J = 7.2, 7.2 Hz, 2H), 2.07-1.90 (m, 6H), 1.76-1.44 (m, 7H), 
1.44-1.19 (m, 23H), 0.85 (dd, J = 6.8, 6.8 Hz, 3H), 0.11 (s, 9H); 13C NMR (100 MHz, 
CDCl3) δ 132.2, 130.6, 107.6, 84.2, 83.0, 81.9, 81.4, 75.4, 73.9, 33.4, 33.3 29.7, 29.63, 
29.60, 29.58, 29.5, 29.3, 29.2, 29.0, 28.9, 28.8, 28.6, 28.4, 27.7, 22.6, 19.8, 14.1; HRMS 







4.96b: Rf  0.56 (50% EtOAc/hexanes); 1H NMR (400 MHz, CDCl3) δ 5.46-5.33 (m, 2H), 
4.69 (ddd, J = 7.2, 7.2, 7.2 Hz, 1H), 3.94-3.85 (m, 2H), 3.85-3.79 (m, 1H), 2.18 (dd, J = 
8.5, 8.5 Hz, 2H), 2.14-1.90 (m, 6H), 1.90-1.71 (m, 2H), 1.67-1.42 (m, 6H), 1.42-1.19 (m, 
21 H), 0.83 (dd, J = 6.8, 6.8 Hz, 3H), 0.10 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 131.9, 
130.7, 109.7, 107.5, 84.2, 82.5, 81.8, 75.4, 71.1, 33.3, 32.2, 31.9, 29.7, 29.60, 29.55, 29.5, 
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29.3, 29.2, 28.84, 28.81, 28.7, 28.5, 27.6, 25.6, 24.5, 22.6, 19.7, 14.1, 0.1; HRMS m/z 









enyl]octahydro-[2,2’]bifuran (4.111). To a rt solution of the isomeric mixture of 4.96 
(380 mg, 0.73 mmol) in CH2Cl2/CH3CN (2 mL, 9:1) was added TPAP (13 mg, 37 μmol), 
N-methylmorpholine oxide (200 mg, 1.5 mmol) and 4 Å MS. After 3 h, the reaction 
mixture was filtered through a SiO2 plug (EtOAc) and concentrated. Purification of the 
residual oil using flash chromatography on SiO2 (10% EtOAc/hexanes) provided the title 
compound as a colorless oil (319 mg, 85%). Rf 0.42 (20% EtOAc/hexanes); 1H NMR 
(300 MHz, CDCl3) δ 5.56- 5.36 (m, 2H), 4.73 (ddd, J = 5.0, 8.5, 8.5 Hz, 1H), 4.43 (dd, J 
= 2.8, 2.8 Hz, 1H), 4.09 (ddd, J = 6.7, 6.7, 6.7, 1H), 3.99 (ddd, J = 6.7, 6.7, 8.2 Hz, 1H), 
2.64 (ddd, J = 7.2, 7.2, 17.9 Hz, 1H), 2.53 (ddd, J = 7.4, 7.4, 17.9 Hz, 1H), 2.32-2.18 (m, 
1H), 2.22 (dd, J = 7.2, 7.2 Hz, 2H), 2.16, 1.70 (m, 8H), 1.67-1.46 (m, 5H), 1.45-1.19 (m, 
20H), 0.89 (dd, J = 6.1, 6.1 Hz, 3H), 0.15, 9H); 13C NMR (75 MHz, CDCl3) δ 212.5, 
132.3, 130.6, 107.3, 84.4, 83.4, 82.9, 80.9, 75.5, 37.9, 33.4, 31.9, 29.7, 29.63, 29.60, 









[2,2’]bifuran (4.112). To a rt solution of 4.96a (261 mg, 0.50 mmol) in MeOH (1.8 mL) 
and Et2O (0.4 mL) was added K2CO3 (50 mg, 0.36 mmol). After 8 h, the reaction mixture 
was diluted with H2O and extracted with Et2O. The combined extracts were washed with 
brine, dried (Na2SO4), filtered and concentrated. Purification of the residue by flash 
chromatography on SiO2 (11% EtOAc/hexanes) provided the title compound as a 
colorless oil (213 mg, 95%): Rf 0.58 (50% EtOAc/hexanes); 1H NMR (400 MHz, CDCl3) 
δ 5.48-5.34 (m, 2H), 4.68 (ddd, J = 5.5, 8.2, 8.2 Hz, 1H), 3.92 (ddd, J = 6.2, 6.2, 8.5 Hz, 
1H), 3.86 (ddd, J = 5.8, 5.8, 7.9 Hz, 1H), 3.80 (ddd, J = 6.5, 6.5, 8.2 Hz, 1H), 3.36 (ddd, J 
= 4.1, 6.8, 7.6 Hz, 1H), 2.39 (br s, 1H), 2.15 (ddd, J = 2.7, 7.2 Hz, 2H), 2.10-1.80 (m, 
7H), 1.76-1.43 (m, 7H), 1.43-1.18 (m, 24H), 0.84 (dd, J = 6.8, 6.8 Hz, 3H); 13C NMR 
(100 MHz, CDCl3) δ 132.2, 130.6, 84.6, 83.0, 81.9, 81.4, 75.4, 73.9, 68.1, 33.34, 33.26, 
31.9, 29.7, 29.59, 29.58, 29.5, 29.3, 29.2, 29.0, 28.8, 28.7, 28.38, 28.36, 27.7, 25.1, 22.6, 












[2,2’]bifuran (4.97). A solution of 4.112 (207 mg, 0.46 mmol) in DMF (2.5 mL) was 
added dropwise to a suspension of NaH (29 mg, 0.95%, 1.2 mmol) and NBu4I (17 mg, 46 
μmol) in DMF (2.5 mL) at 0 °C. After 15 min, BnBr (0.18 mL, 1.4 mmol) was added 
dropwise. After 2 h, NH4Cl (5 mL, sat’d) was added and the resulting mixture was 
extracted with Et2O. The combined extracts were washed with brine, dried (Na2SO4), 
filtered and concentrated. Purification of the residue by flash chromatography on SiO2 
(8% EtOAc/hexanes) provided the title compound as a colorless oil (234 mg, 94%): Rf 
0.72 (50% EtOAc/hexanes); 1H NMR (400 MHz, CDCl3) δ 7.38-7.29 (m, 4H), 7.28-7.26 
(m, 1H), 5.51-5.37 (m, 2H), 4.74 (d, J = 11.6 Hz, 1H), 4.75-4.70 (m, 1H), 4.59 (d, J = 
11.6, 1H), 4.12 (ddd, J = 5.8, 5.8, 8.9 Hz, 1H), 4.02-3.92 (m, 2H), 3.38 (ddd, J = 5.8, 5.8, 
5.8 Hz, 1H), 2.16 (ddd, J = 2.7, 7.2, 7.2 Hz, 2H), 2.12-1.90 (m, 7H), 1.90-1.19 (m, 29H), 
0.88 (dd, J = 6.5, 6.5 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 139.2, 132.2, 130.8, 128.2, 
127.9, 127.3, 84.6, 81.7, 81.6, 81.15, 81.10, 75.3, 72.7, 68.1, 33.4, 31.9, 30.5, 29.7, 29.65, 
29.62, 29.60, 29.5, 29.32, 29.26, 28.83, 28.80, 28.2, 27.7, 25.3, 22.7, 18.3, 14.1; HRMS 











11-benzyloxy-2-hydroxyundec-4-ynyl}-5-methyl-5H-furan-2-one (4.98). A solution of 
4.97 (217 mg, 0.41 mmol) in THF (1 mL) was cooled to -78 °C and n-BuLi (150 μL, 2.59 
M, 0.39 mmol) was added dropwise. After 15 min, BF3•OEt2 (51 μL, 0.40 mmol) was 
added dropwise and after an additional 30 min, a solution of 4.75 (37 mg, 0.24 mmol) in 
THF (0.5 mL) was added dropwise. After 3 h, MeOH (1 mL) was added and the reaction 
mixture was poured cold into a stirred solution of NH4Cl (20 mL, sat’d). The resulting 
mixture was extracted with Et2O and the combined extracts were dried (Na2SO4), filtered 
and concentrated. Purification of the residue by flash chromatography on SiO2 (40% 
EtOAc/hexanes) provided the title compound as a colorless oil (90 mg, 62%, 89% 
BRSM): Rf 0.43 (50% EtOAc/hexanes); 1H NMR (400 MHz, CDCl3) δ 7.36-7.26 (m, 
4H), 7.26-7.21 (m, 1H), 7.20 (d, J = 1.0 Hz, 1H), 5.49- 5.32 (m, 2H), 5.02 (dddd, J = 1.4, 
6.8, 6.8, 6.8 Hz, 1H), 4.74-4.67 (m, 1H), 4.72 (d, J = 11.6, 1H), 4.56 (d, J = 11.6 Hz, 1H), 
4.14-4.06 (m, 1H), 4.00-3.89 (m, 3H), 3.36 (ddd, J = 7.9, 7.9, 7.9 Hz, 1H), 2.57 (dddd, J 
= 1.7, 1.7, 3.8, 15.4 Hz, 1H), 2.49 (dddd, J = 1.5, 1.5, 8.2, 15.4 Hz, 1H), 2.39 (dddd, J = 
2.4, 2.4, 5.8, 16.8 Hz, 1H), 2.33 (dddd, J = 2.4, 2.4, 6.2, 16.8 Hz, 1H), 2.16-1.85 (m, 8H), 
1.85-1.18 (m, 28H), 1.40 (d, J = 6.8 Hz, 3H), 0.85 (dd, J = 6.5, 6.5 Hz, 3H); 13C NMR 
(100 MHz, CDCl3) δ 174.4, 152.1, 139.1, 132.2, 130.8, 130.6, 128.2, 127.9, 127.3, 83.7, 
81.64, 81.60, 81.2, 81.1, 78.0, 75.4, 75.3, 72.7, 68.3, 33.4, 32.0, 31.9, 30.5, 29.7, 29.62, 
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29.60, 29.58, 29.3, 29.2, 29.0, 28.9, 28.8, 28.2, 28.1, 27.7, 27.5, 25.4, 22.6, 19.0, 18.6, 










2,11-dihydroxy-undec-4-ynyl}-5-methyl-5H-furan-2-one (4.99). A solution of 4.98 (75 
mg, 0.11 mmol) in 1,2-dichloroethane (2 mL), H2O (0.16 mL), and pH 7 buffer solution 
(0.16 mL) was protected from light and heated to 50 °C. To this solution was added DDQ 
(184 mg, 0.8 mmol) in one portion, and the resulting mixture was stirred at 50 °C for 2 h. 
The mixture was allowed to cool and diluted with CH2Cl2, washed with aqueous 
NaHCO3 (sat’d), dried (Na2SO4), filtered and concentrated. Purification of the residue by 
flash chromatography on SiO2 (elution gradient: 60% EtOAc/hexanes to 80% 
EtOAc/hexanes) provided the title compound as a colorless oil (15 mg, 23%): Rf 0.24 
(50% EtOAc/hexanes); 1H NMR (400 MHz, CDCl3) δ 7.23 (d, J = 1.0 Hz, 1H), 5.52-5.36 
(m, 2H), 5.03 (dq, J = 1.4, 6.8 Hz, 1H), 4.72 (ddd, J = 7.2, 7.2, 7.2 Hz, 1H), 4.01-3.78 (m, 
4H), 3.42-3.36 (m, 1H), 2.63-2.43 (m, 2H), 2.43-1.84 (m, 12H), 1.76-1.17 (m, 35H), 1.84 
(dd, J = 6.5, 6.5 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 174.5, 152.1, 132.2, 130.63, 
130.58, 83.6, 83.0, 82.0, 81.5, 78.0, 75.4, 74.0, 68.4. 33.4, 33.3, 32.0, 31.9, 29.7, 29.64, 
29.61, 29.59, 29.5, 29.32, 29.26, 29.0, 28.9, 28.84, 28.78, 28.4, 27.7, 27.5, 25.1, 22.7, 






(  )12 (  )7
4.113  
3-{(2S,11R)-11-[(2R,2’R,5R,5’R)-5’-tridecanyloctahydro-[2,2’]bifuran-5-yl]-11-
benzyloxy-2-hydroxyundecanyl}-5-methyl-5H-furan-2-one (4.113). A solution of 4.98 
(52 mg, 75 μmol) and p-toluenesulfonyl hydrazide (2.6 g, 14 mmol) in ethylene glycol 
dimethyl ether (13 mL) was heated at reflux. An aqueous solution of NaOAc (10.9 mL, 
1.6 M, 17 mmol) was added over 4 h by syringe pump. The mixture was refluxed for an 
additional 1 h and allowed to cool to rt. The layers were separated and the aqueous layer 
was extracted with EtOAc. The combined organic layers were dried (Na2SO4), filtered 
and concentrated. Purification of the crude material by flash chromatography on SiO2 
(elution gradient: 40% EtOAc/hexanes to 60% EtOAc/hexanes) gave a colorless oil (48 
mg, 69 μmol, 92%): Rf 0.28 (40% EtOAc/hexanes); 1H NMR (300 MHz, CDCl3) δ 7.35-
7.20 (m, 5H), 7.16 (d, J = 1.0 Hz, 1H), 5.02 (dq, J = 1.3, 6.7 Hz, 1H), 4.71 (d, J = 11.5 
Hz, 1H), 4.56 (d, J = 11.5 Hz, 1H), 4.14-4.02 (m, 1H), 3.88-3.76 (m, 1H), 2.55-2.25 (m, 
3H), 2.06-1.82 (m, 4H), 1.79-1.52 (m, 4H), 1.50-1.15 (m, 41H), 1.40 (d, J = 6.7 Hz, 3H), 
0.85 (dd, J = 6.9, 6.9 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 174.6, 151.8, 139.2, 131.1, 
128.1, 127.9, 127.3, 81.8, 81.5, 81.3, 79.8, 77.9, 72.7, 69.9, 37.4, 35.8, 33.3, 31.9, 30.5, 







(  )12 (  )7
22-Deoxysquamotacin  
22-Deoxysquamotacin. The title compound was prepared from 4.113 (35 mg, 50 μmol) 
using the general procedure described for 4.99 (colorless oil, 28 mg, 94%): Rf 0.38 (60% 
EtOAc/hexanes); 1H NMR (400 MHz, CDCl3) δ 7.16 (d, J = 1.4 Hz, 1H), 5.02, (dq, J = 
1.4, 6.8 Hz, 1H), 3.94-3.76 (m, 5H), 3.35 (ddd, J = 6.8, 6.8, 6.8 Hz; 1H), 2.49 (dddd, J = 
1.7, 1.7, 3.4, 15.0 Hz, 1H), 2.39 (br s, 2H), 2.36 (dddd, J = 1.4, 1.4, 8.2, 15.0 Hz, 1H), 
2.02-1.86 (m, 5H), 1.68-1.55 (m, 5H), 1.50-1.17 (m, 50H), 0.84 (dd, J = 6.8, 6.8 Hz, 3H); 
13C NMR (75 MHz, CDCl3) δ 174.6, 151.8, 151.1, 83.0, 82.1, 81.2, 78.0, 74.0, 69.9, 37.3, 
35.8, 33.3, 32.0, 31.9, 29.7, 29.64, 29.62, 29.56, 29.4, 29.3, 28.9, 28.3, 26.1, 25.6, 25.5, 
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